WO2016027842A1 - 幹細胞の分化状態の判定方法及びこれに用いられる新規な分化マーカー - Google Patents
幹細胞の分化状態の判定方法及びこれに用いられる新規な分化マーカー Download PDFInfo
- Publication number
- WO2016027842A1 WO2016027842A1 PCT/JP2015/073281 JP2015073281W WO2016027842A1 WO 2016027842 A1 WO2016027842 A1 WO 2016027842A1 JP 2015073281 W JP2015073281 W JP 2015073281W WO 2016027842 A1 WO2016027842 A1 WO 2016027842A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- foxb2
- mrna
- seq
- cells
- differentiation
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Definitions
- the present invention relates to a novel differentiation marker that can determine the differentiation state of stem cells at an early stage of differentiation.
- Pluripotent stem cells such as ES cells (Embryonic ES Stem cells) and iPS cells (Induced Pluripoent Stem Cells, induced pluripotent stem cells) are co-cultured with feeder cells, for example, to maintain their pluripotency Culturing in a feeder-derived conditioned medium (CM), adding basic FGF (bFGF / FGF2, basic Fibroblast Growth Factor, basic fibroblast growth factor) or LIF (leukemia inhibitor factor) to the medium is required. Otherwise, it may lose its pluripotency due to the environment and cell condition and easily differentiate. Therefore, it is important to accurately know the undifferentiated state (state having pluripotency) and the differentiated state of stem cells.
- CM feeder-derived conditioned medium
- basic FGF basic Fibroblast Growth Factor
- LIF leukemia inhibitor factor
- transplantation is performed after differentiating pluripotent stem cells into target cells. If the cells to be transplanted contain undifferentiated cells, this may cause tumor formation. There is a risk of becoming. Therefore, a technique for determining whether or not undifferentiated stem cells are mixed in differentiation-induced pluripotent stem cells is important.
- pluripotent stem cells As a method of determining the differentiation state of pluripotent stem cells, a method of detecting a marker that is an indicator of the differentiation state has been performed.
- Alkaline Phosphatase, Nanog, Oct4, TRA-1-60, Sox, LIF-R and the like are known as pluripotent markers of pluripotent stem cells. Since pluripotent stem cells express these markers in an undifferentiated state, it is possible to determine whether or not the stem cells maintain an undifferentiated state by detecting these markers. However, the differentiation state of these markers cannot be determined unless the stem cells are differentiated to some extent (for example, up to one of the three germ layers). Therefore, it is difficult to determine whether the undifferentiated cells maintain their undifferentiated state (pluripotency) or have acquired the ability to differentiate in the future at the initial stage of differentiation after differentiation induction. there were.
- Non-patent Document 1 a group of transcription factors having a forkhead or winged helix DNA binding domain called Fox (Forkhead box) is known (Non-patent Document 1), and it is known that there are about 50 types in humans. (FOXB1, FOXB2, etc.). Fox proteins are known to function mainly as developmental regulators, tissue-specific regulators, and cell cycle regulators, but some of the actions have not been elucidated.
- An object of the present invention is to provide a method capable of determining the differentiation state of undifferentiated stem cells at an early stage of differentiation.
- the present invention has been made for the purpose of solving the above-described problems, and has the following configuration.
- (1) A method for determining the differentiation state of a cell, wherein the expression of a FOXB2 gene in a stem cell is detected and a determination is made based on the result.
- (2) A differentiation marker selected from mRNA or protein derived from FOXB2 gene.
- undifferentiated cells such as ES cells and iPS cells are cultured in a medium supplemented with basic FGF (bFGF, FGF2, basic Fibroblast Growth Factor, basic fibroblast growth factor)
- bFGF basic Fibroblast Growth Factor
- basic fibroblast growth factor basic FGF
- iPS cells are cultured in a bFGF-free medium (differentiation induction treatment), and FOXB2 mRNA expression of iPS cells is detected 3 to 5 days after the start of the culture. Moreover, the phenomenon that the expression level is remarkably increased was confirmed. It was also confirmed that FOXB2 mRNA expression was not confirmed in iPS cells cultured in a medium supplemented with bFGF and maintained in an undifferentiated state. From the above, it has been found that FOXB2 mRNA is useful as a differentiation marker for ES cells and iPS cells, and by measuring its expression, cells at an early stage of differentiation can be selected. It came to complete.
- the differentiation state of stem cells can be determined at the initial stage of differentiation.
- the present invention can also be applied to stem cell quality control and differentiated cell preparation / isolation methods. Furthermore, since the present invention can determine differentiated cells at the early stage of culture, it is useful for early screening of cells and quality control of stem cells, and can be expected to shorten the culture period and reduce the cost of the medium.
- FIG. 2 is an electrophoretogram showing the results of detection of FOXB2 mRNA expression in hiPS cells obtained by Example 1 by RT-PCR.
- FIG. 1 (1) shows the result of detecting the expression of FOXB2 mRNA
- (2) shows the result of detecting the expression of GAPDH mRNA
- (3) shows the result of detecting the expression of OCT3 / 4 mRNA
- (4 ) Shows the result of detecting the expression of NANOG mRNA
- (5) shows the result of detecting the expression of SOX2 mRNA.
- It is an electrophoretic diagram which shows the result of having examined the expression of FOXB2 mRNA obtained in Example 2 by RT-PCR method.
- FIG. 5 is a photograph of hiPS cells cultured in a bFGF-free medium obtained in Reference Example 1 (FIG. 5 (1)) and a photograph of hiPS cells cultured in a bFGF-added medium (FIG. 5 (2)).
- the stem cells according to the present invention include cells having so-called self-renewal ability and differentiation ability capable of differentiating into various cells.
- ES cells and iPS cells which are undifferentiated cells with pluripotency (pluripotency), ntES cells (nuclear transfer Membryonic cell Stem Cell), EG cells (Embryonic cell, embryonic germ cells), EC cells (Embryonic Cell, embryonic cancer stem cell) and the like.
- stem cell-derived animals include mammals such as humans, cows, horses, dogs, guinea pigs, mice, and rats.
- Stem cells which are test cells used in the method for determining the differentiation state of cells of the present invention, include stem cells that have been subjected to a known differentiation-inducing treatment, stem cells that have been treated to maintain an undifferentiated state, and known pluripotency Examples include somatic cells that have been subjected to sex induction treatment and have been dedifferentiated.
- the method for inducing differentiation of undifferentiated stem cells may be any method known per se and is not particularly limited.
- a method of culturing cells after treating them with a known differentiation inducer a method of culturing undifferentiated stem cells in an environment in which differentiation is induced, such as culturing in a medium not containing bFGF or LIF, and the like can be mentioned.
- Examples of chemical substances that induce differentiation of undifferentiated stem cells include, for example, retinoic acid that induces differentiation into neurons, spermine that induces differentiation into cardiomyocytes, and sodium butyrate ( Sodium-Butyrate), Trichostatin A (Trichostatin A), DNA methyltransferase inhibitors that induce differentiation of mouse ES cells into insulin-producing cells (DNA-Methyltransferase Inhibitor), and the like are known.
- Undifferentiated state means, for example, that a cell is in a state having the above-described self-renewal ability and differentiation ability capable of differentiating into various cells.
- the “treatment for maintaining the undifferentiated state” may be any known process for maintaining the undifferentiated state of stem cells, for example, co-culture with feeder cells, addition of bFGF or LIF into the medium, etc. Can be mentioned.
- the FOXB2 gene means a gene DNA, RNA or the like encoding a FOXB2 protein present in an animal species from which a cell subjected to determination is derived. Also included are genes encoding homologues, mutants, and derivatives of the FOXB2 protein. Furthermore, the base sequence that hybridizes with these genes under stringent conditions and the gene containing the same, and the FOXB2 gene have a sequence homology of 70%, preferably 80%, more preferably 95%, and even more preferably 97% or more. A gene having a nucleotide sequence having sex is also included.
- the human FOXB2 gene has a gene corresponding to the base sequence represented by SEQ ID NO: 1 (base sequence of human FOXB2 mRNA) and the base sequence encoding the protein represented by SEQ ID NO: 2.
- SEQ ID NO: 1 base sequence of human FOXB2 mRNA
- SEQ ID NO: 2 base sequence of human FOXB2 mRNA
- examples thereof include genes or genes having a sequence homology of 70%, preferably 80%, more preferably 95%, and still more preferably 97% or more with these base sequences.
- mouse Foxb2 gene a gene corresponding to the base sequence represented by SEQ ID NO: 34 (base sequence of mouse Foxb2 mRNA), a gene having a base sequence encoding the protein represented by SEQ ID NO: 35, or these Examples thereof include genes having a base sequence having 70%, preferably 80%, more preferably 95%, and still more preferably 97% or more sequence homology with the base sequence.
- FOXB2 mRNA examples include mRNA transcribed from the FOXB2 gene present in the animal species from which the cells subjected to determination are derived, for example, the mRNA derived from the FOXB2 gene described above.
- mRNA derived from the FOXB2 gene examples include the following as human FOXB2 mRNA.
- -MRNA having the base sequence represented by SEQ ID NO: 1 GenBank Accession No. NM_001013735
- -MRNA encoding the amino acid sequence represented by SEQ ID NO: 2
- MRNA encoding an amino acid sequence in which 1 to several, preferably 1 to 5, more preferably 1 to 3 amino acids of the amino acid sequence represented by SEQ ID NO: 2 have been deleted, inserted, added or substituted
- An mRNA encoding an amino acid sequence having 70%, preferably 80%, more preferably 95%, and still more preferably 97% or more sequence homology with the amino acid sequence represented by SEQ ID NO: 2.
- mouse Foxb2 mRNA includes the following. -MRNA having the base sequence represented by SEQ ID NO: 34 (GenBank Accession No. NM_008023) -MRNA having a base sequence having a sequence homology of 70%, preferably 80%, more preferably 95%, and even more preferably 97% or more with the base sequence represented by SEQ ID NO: 34 -MRNA encoding the amino acid sequence represented by SEQ ID NO: 35 -MRNA encoding an amino acid sequence in which 1 to several, preferably 1 to 5, more preferably 1 to 3 amino acids of the amino acid sequence represented by SEQ ID NO: 35 have been deleted, inserted, added or substituted -MRNA encoding an amino acid sequence having a sequence homology of 70%, preferably 80%, more preferably 95%, even more preferably 97% or more with the amino acid sequence represented by SEQ ID NO: 2.
- the FOXB2 protein according to the present invention includes a protein translated from the FOXB2 gene present in the animal species from which the cells to be subjected to determination are derived. Such homologues, mutants, and derivatives of FOXB2 protein may be used.
- human FOXB2 protein examples include the following.
- mouse FOXB2 protein examples include the following.
- the method for determining the differentiation state of a cell of the present invention is “a method for determining the differentiation state of a cell, wherein the expression of a FOXB2 gene in a stem cell is detected and a determination is made based on the result”.
- Method for detecting FOXB2 gene expression examples include a method for detecting FOXB2 mRNA expression, and a method for detecting FOXB2 protein expression.
- detecting expression refers to “detecting whether FOXB2 gene is expressed (for example, the presence or absence of FOXB2 mRNA or FOXB2 protein)” and “amount of FOXB2 gene expressed (for example, FOXB2). the amount of mRNA or the amount of FOXB2 protein is measured.
- Detection of the expression of the FOXB2 gene is performed after the test cells after differentiation induction treatment express FOXB2 mRNA or FOXB2 protein to a level that can be detected. Specifically, after subjecting a test cell to differentiation induction, the upper limit is within 7 days, preferably within 6 days, more preferably within 5 days, and the lower limit is over 1 day, preferably over 2 days, more preferably over 3 days. After culturing as described above, cells may be collected and the following expression of FOXB2 gene may be detected. During this time, cells may be collected daily to detect the expression of the FOXB2 gene.
- the method for detecting the expression of FOXB2 mRNA is not particularly limited as long as it is a method for detecting mRNA per se, and may be appropriately selected from known methods.
- RT-PCR reverse Transcription Polymerase Chain Reaction
- real-time RT-PCR competitive PCR
- competitive PCR in situ PCR
- DNA array method DNA array method
- Northern hybridization Northern hybridization
- FISH method dot blot method
- RNase protection assay method RT-LAMP method
- SmartFlare that uses a complementary strand (capture strand) for target RNA bound to gold nanoparticles and a reporter strand that is the complementary strand of the capture strand TM method
- detection method using two types of fluorescent probes Reduction-triggered Fluorescence activation probe, RETF probe
- detection method using aromatic nucleophilic substitution reaction (complementary to target RNA) CNs-AMCA modified with aminocoumarin protected with 2-cyano-4-nitrobenzenesulfonyl group bound to various DNAs Lobe and, a method of a method) or the like using the MBA probe modified with thiophenol group attached the DNA complementary to the target RNA.
- RT-PCR method is a method in which a target FOXB2 gene (for example, FOXB2 mRNA) is used as a template, cDNA is synthesized by reverse transcription, and then amplified by PCR [Kawasaki, ES, et al In PCR Protocol, A Guide to methods and applications, Academic Press, Inc., San Diego, 21-27 (1991)].
- the conditions for the reverse transcription reaction and the DNA amplification reaction are not particularly limited, and optimum conditions can be adopted as appropriate.
- the amplification region of the target gene (for example, FOXB2 mRNA) does not necessarily have the full length, and may be a partial region of the gene as long as there is no problem in confirming the amplification product.
- the amplified cDNA amount (corresponding to the amount of mRNA) may be detected, for example, by subjecting the DNA amplification reaction solution to electrophoresis and using a probe that specifically hybridizes to the target amplified fragment.
- mRNA is first extracted and separated from a test cell by a known method.
- RT-PCR was performed using the mRNA obtained above as a template, and complementary to FOXB2 mRNA or a partial region thereof.
- cDNA single-stranded DNA
- the presence or amount of FOXB2 mRNA in the cell can be detected by detecting the presence or absence (amount) of the amplified product (cDNA).
- amplification primer used above examples include, for example, a primer having the base sequence represented by SEQ ID NO: 4 when detecting human FOXB2 mRNA.
- a primer having the base sequence represented by SEQ ID NO: 37 can be mentioned.
- the nucleic acid amplification reaction When the nucleic acid amplification reaction is performed using the cDNA amplified by the above method as a template, it may be performed by a real-time amplification detection method.
- An example of the detection method by the real-time amplification detection method is a real-time PCR detection method.
- Examples of the real-time PCR detection method include a normal intercalator method for performing real-time PCR using an intercalator (eg, SYBR TM Green I), a TaqMan TM real-time PCR method, an MGB Eclipse Probe System method, a Molecular Beacons Probe Technology method, Examples include, but are not limited to, the LUX Fluorogenic Primer method, the Quenching probe-PCR (QP) method, and the cycling probe method.
- an intercalator eg, SYBR TM Green I
- TaqMan TM real-time PCR method e.g., MGB Eclipse Probe System method
- MGB Eclipse Probe System method e.g., MGB Eclipse Probe System method
- Molecular Beacons Probe Technology method examples include, but are not limited to, the LUX Fluorogenic Primer method, the Quenching probe-PCR (QP) method, and the cycling probe method.
- the “primer pair prepared so that the FOXB2 mRNA target region can be amplified” used in the above PCR is a primer pair that amplifies the base sequence of FOXB2 mRNA or a specific region (partial sequence) thereof. Is mentioned.
- Examples of such a primer pair include a primer pair that amplifies human FOXB2 mRNA (base sequence represented by SEQ ID NO: 1) or a specific region (partial sequence) thereof. Specifically, for example, when targeting the 179 bp region (SEQ ID NO: 3) at positions 45 to 223 of the base sequence represented by SEQ ID NO: 1, a primer and a sequence having the base sequence represented by SEQ ID NO: 9 The primer pair of the primer which has a base sequence represented by number 10 is mentioned.
- a primer pair that amplifies mouse Foxb2 mRNA (base sequence represented by SEQ ID NO: 34) or a specific region (partial sequence) thereof is also included.
- the primer and sequence having the base sequence represented by SEQ ID NO: 45 The primer pair of the primer which has a base sequence represented by number 46 is mentioned.
- a specific example of a method for detecting human FOXB2 mRNA by RT-PCR is as follows.
- FOXB2 mRNA amplification primer for example, primer having the nucleotide sequence of SEQ ID NO: 4
- 1 ⁇ L of FOXB2 mRNA amplification primer 1 ⁇ L to total RNA 500 ng to 10 ⁇ g extracted from test cells and treated with DNase, 65-80 ° C, 2-5 minutes
- the reverse transcription reaction is carried out by incubating at 37-50 ° C. for 20-60 minutes. Thereafter, the obtained cDNA is recovered by a conventional method.
- forward primer for example, a primer having the base sequence of SEQ ID NO: 9
- reverse primer for example, primer having the base sequence of SEQ ID NO: 10.
- a reaction of 94 ° C. for 2 minutes, 98 ° C. for 10 seconds ⁇ 56 ° C. for 20 seconds ⁇ 68 ° C. for 30 seconds is performed for about 28 to 30 cycles.
- the amplified product is detected and analyzed by electrophoresis, for example, to detect FOXB2 mRNA.
- an intercalator eg, SYBR TM Green I
- a polymerase such as Taq DNA polymerase is used.
- the amplification product is detected and analyzed by measuring the fluorescence intensity of the intercalator that intercalates in correlation with the amplification amount of the amplification product, and FOXB2 mRNA is detected.
- capillary electrophoresis J. Chromatogr. 593 253-258 (1992), Anal. Chem. 64 1926-1932 (1992), WO2007 / 027495, etc.
- capillary chip electrophoresis After collecting the cDNA, a signal derived from the labeled PCR amplification product separated by capillary chip electrophoresis may be detected by a detector using a primer or intercalator labeled with a labeling substance such as a fluorescent substance.
- the detector may be made by a device such as a differential refraction detector, a fluorescence detector, a UV detector, etc. Among them, a UV detector and a fluorescence detector are preferable, and a fluorescence detector is more preferable.
- a device such as a differential refraction detector, a fluorescence detector, a UV detector, etc.
- a UV detector and a fluorescence detector are preferable, and a fluorescence detector is more preferable.
- an automatic immunoanalyzer such as LiBASys (manufactured by Shimadzu Corporation) is used, operations from PCR to electrophoresis can be performed in real time.
- a method for detecting FOXB2 mRNA by Northern hybridization method for example, mRNA extracted / separated from a test cell is immobilized on an appropriate carrier, and a base sequence complementary to FOXB2 mRNA is prepared. Examples include a method of detecting FOXB2 mRNA in a test cell by performing hybridization with a labeled probe (may be cDNA) and detecting the degree thereof.
- the probe used here may be composed of the entire complementary sequence of the base sequence of FOXB2 mRNA or may be composed of a part of the base sequence. Further, a microarray or DNA chip on which the probe is immobilized can also be used for this detection method.
- the reagents used in the method for detecting FOXB2 mRNA according to the present invention include reagents usually used in this field, such as buffers, stabilizers, preservatives, etc. Those that do not inhibit the property and do not inhibit the nucleic acid amplification reaction such as PCR or the hybridization reaction can be used. In addition, the concentration may be appropriately selected from a concentration range usually used in this field.
- buffer solutions include, for example, when performing nucleic acid amplification reactions and hybridization reactions such as normal PCR, such as Tris buffer solution, phosphate buffer solution, veronal buffer solution, borate buffer solution, Good buffer solution, etc. All the buffers used are mentioned.
- the pH is not particularly limited, and examples thereof include a range of 5 to 9.
- a nucleic acid synthase DNA polymerase, RNA polymerase, reverse transcriptase, etc.
- a substrate dNTP, rNTP, etc.
- a double-stranded intercalator ethidium bromide, SYBR TM Green, etc.
- Labeled detection substances such as FAM and TAMRA are used.
- FOXB2 mRNA can be detected without destroying the test cells.
- the technique can be used to detect FOXB2 protein in the nucleus without destroying cells.
- the nuclear membrane of the test cell is partially solubilized using a buffer containing a surfactant such as Triton TM , NP-40, Tween 20 TM , Saponin, Digitonin TM , Leucoperm TM .
- a surfactant such as Triton TM , NP-40, Tween 20 TM , Saponin, Digitonin TM , Leucoperm TM .
- the nuclear protein is stained with an anti-FOXB2 antibody labeled with a fluorescent substance or the like, the FOXB2 protein in the nucleus can be detected.
- FOXB2 protein may be detected by staining the nuclear FOXB2 protein using these commercially available reagents.
- FOXB2 protein can also be detected by the following method for destroying cells.
- test cell culture is subjected to conventional methods such as filtration or centrifugation, and the cells or cells are collected and suspended in an appropriate buffer.
- conventional methods such as filtration or centrifugation, and the cells or cells are collected and suspended in an appropriate buffer.
- surfactant treatment for example, surfactant treatment, ultrasonic treatment, lysozyme treatment, freeze-thawing, etc.
- an extract containing FOXB2 protein is obtained by methods such as centrifugation and filtration.
- the FOXB2 protein in the obtained extract may be detected by a method known per se for detecting a protein.
- Methods for detecting FOXB2 protein in the extract include, for example, so-called enzyme immunoassay (EIA), radioimmunoassay (RIA) using a substance having affinity for FOXB2 protein (eg, antibody),
- EIA enzyme immunoassay
- RIA radioimmunoassay
- known immunological measurement methods such as enzyme-linked immunosorbent assay (ELISA), fluorescence immunoassay (FIA), Western blotting, immunohistochemistry, antibody array method, measurement method by simple immunochromatography, etc.
- ELISA enzyme-linked immunosorbent assay
- FFA fluorescence immunoassay
- Western blotting immunohistochemistry
- antibody array method measurement method by simple immunochromatography, etc.
- HPLC high performance liquid chromatography
- electrophoresis capillary electrophoresis
- capillary chip electrophoresis and the like
- Examples of the measurement principle include, but are not limited to, a sandwich method, a competitive method, a two
- FOXB2 protein may be detected by a measurement method according to an immunoagglutination method such as an immunoratio method or an immunoturbidimetric method. These detection methods may be performed according to a method known per se.
- the antibody against FOXB2 protein (anti-FOXB2 antibody) used to detect FOXB2 protein may be any antibody that can recognize FOXB2 protein, its partial peptide, or salts thereof. There is no particular limitation.
- any of a polyclonal antibody and a monoclonal antibody may be used, and these may be used alone or in appropriate combination.
- these antibodies may be used as F (ab ′) 2 , Fab ′, or Fab after digestion with an enzyme such as pepsin or papain, if necessary.
- a commercially available antibody against FOXB2 protein can also be used.
- the antibody may be labeled with a labeling substance.
- labeling substances used for labeling include alkaline phosphatase, ⁇ -galactosidase, peroxidase, microperoxidase, glucose oxidase, glucose-6-phosphate dehydrogenase, acetylcholinesterase used in EIA (ELISA), Enzymes such as malate dehydrogenase and luciferase, for example, radioactive isotopes such as 99m Tc, 131 I, 125 I, 14 C and 3 H used in RIA, such as fluorescein, dansyl and fluorescamine used in FIA, Fluorescent substances such as coumarin, naphthylamine or derivatives thereof, for example, luminescent substances such as luciferin, isoluminol, luminol, bis (2,4,6-trifluorophenyl) oxalate, such as phenol, naphthol, anthracene or
- antibody against the FOXB2 protein examples include “an antibody against the protein having the amino acid sequence represented by SEQ ID NO: 2” and “an antibody against the protein having the amino acid sequence represented by SEQ ID NO: 35”.
- the reagent used to detect the FOXB2 protein, the concentration at the time of detection, the measurement conditions for carrying out the detection, etc. (reaction temperature, reaction time, pH at the time of reaction, measurement wavelength, measuring device, etc.) May be set according to the measurement method of the above-mentioned immunological measurement method known per se, and any automatic analyzers, spectrophotometers, etc. that are usually used in this field are exceptions. Can be used without.
- differentiated / differentiated or “differentiated state” means a state in which a cell is in an “early differentiation stage” state, “a state that has acquired differentiation ability to be differentiated in the future (differentiation induction)”, and “ This includes cases in any state of "differentiated”.
- “differentiated / differentiated” or “differentiated state” means a state in which a cell is in an “early differentiation stage” state or “acquired differentiation ability to differentiate in the future (differentiation-induced)”. This is the case in either state.
- the initial stage of differentiation means early after differentiation induction treatment, specifically, up to 7 days, preferably up to 6 days, more preferably 3 to 5 days after differentiation induction treatment. The time until.
- the initial stage of differentiation refers to a stage before undifferentiated stem cells differentiate into one of the three germ layers, and an undifferentiated marker after differentiation induction treatment (eg, OCT3 / 4 , NANOG , SOX2, etc.). Including a stage before disappearance.
- an undifferentiated marker after differentiation induction treatment eg, OCT3 / 4 , NANOG , SOX2, etc.
- Examples of the differentiation state determination method of the present invention include the following methods.
- Examples of the method of judging based on the result of detecting FOXB2 mRNA include the following methods. 1) When FOXB2 mRNA in a test cell is detected by the above method and FOXB2 mRNA is detected, it is determined that the test cell is differentiated.
- FOXB2 mRNA of the test cell performs detection of FOXB2 mRNA of the test cell, to detect similarly FOXB2 mRNA with undifferentiated stem cells that are undifferentiated state as compared was confirmed.
- the detected amount of FOXB2 mRNA of a test cell if greater than the detection of FOXB2 mRNA of undifferentiated stem cells to be compared is determined that the test cell is a state of differentiation, and.
- whether many as compared with the detected amount of FOXB2 mRNA of undifferentiated stem cells detected amount of FOXB2 mRNA is compared in a test cell may be relatively determined by comparing the two.
- Detection of FOXB2 mRNA of the test cell whether large compared to the detected amount of FOXB2 mRNA of undifferentiated stem cells to be compared, the detected amount of FOXB2 mRNA of a test cell, undifferentiated pre measured You may implement by comparing with the detection amount of FOXB2 mRNA of a stem cell.
- the detected amount of FOXB2 mRNA of a test cell, if greater than the detection of FOXB2 mRNA of undifferentiated stem cells previously measured and determined its test cell is a state of differentiation, and.
- a boundary value (cutoff value) that can be used to determine whether or not the test cell is differentiated is set in advance, and whether or not the test cell has a higher FOXB2 mRNA detection amount than the boundary value. You may judge the differentiation state. In this case, when the detected amount of FOXB2 mRNA in the test cell is higher than the cut-off value, it is determined that the test cell is in a differentiated state.
- FOXB2 protein is similarly detected using undifferentiated stem cells that have been confirmed to be in an undifferentiated state as a comparison. Then, when the detected amount of FOXB2 protein in the test cell is larger than the detected amount of FOXB2 protein in the undifferentiated stem cell to be compared, it is determined that the test cell is in a differentiated state. At this time, whether the detected amount of FOXB2 protein in the test cell is larger than the detected amount of FOXB2 protein in the undifferentiated stem cell to be compared may be determined by comparing both.
- the amount of FOXB2 protein detected in the undifferentiated stem cells measured in advance and whether the amount of FOXB2 protein detected in the test cells is higher than the amount detected in the undifferentiated stem cells to be compared You may implement by comparing with the detection amount of FOXB2 protein of a cell. When the detected amount of FOXB2 protein in the test cell is larger than the detected amount of FOXB2 protein in the undifferentiated stem cells measured in advance, the test cell is determined to be in a differentiated state.
- a boundary value (cutoff value) that can be used to determine whether or not the test cell is differentiated is set in advance, and the test is performed depending on whether or not the detected amount of FOXB2 protein in the test cell is higher than the boundary value. You may judge the differentiation state of a test cell. In this case, when the detected amount of FOXB2 protein in the test cell is higher than the cutoff value, it is determined that the test cell is in a differentiated state.
- the following method may be used.
- Undifferentiated stem cells such as iPS cells or ES cells are subjected to differentiation induction treatment by a known method.
- the upper limit after differentiation induction treatment is within 7 days, preferably within 6 days, more preferably within 5 days, and the lower limit is 1 day or more, preferably 2 days or more, more preferably 3 days or more, and then the cells are collected.
- FOXB2 gene expression FOXB2 mRNA expression or FOXB2 protein expression
- FOXB2 gene expression FOXB2 mRNA expression or FOXB2 protein expression
- detection of FOXB2 gene expression in test cells detection of FOXB2 mRNA or FOXB2 protein
- detection of FOXB2 gene expression using undifferentiated stem cells that have been confirmed to be undifferentiated as a comparison. I do.
- the test cell Is determined to be in a differentiated state.
- the detected amount of FOXB2 gene expression in undifferentiated stem cells was compared with the detected amount of FOXB2 gene expression in the test cell, and the FOXB2 gene in the test cell was compared.
- the detected amount of expression is larger than the detected amount of FOXB2 gene expression in the undifferentiated stem cells to be compared, it is determined that the test cell is in a differentiated state.
- a boundary value (cutoff value) that can be used to determine whether or not the test cell is differentiated is set in advance, and the detected amount of FOXB2 mRNA or the detected amount of FOXB2 protein in the test cell When higher than the value, it is determined that the test cell is in a differentiated state.
- the differentiation state determination method of the present invention is applied to undifferentiated stem cells that have not been subjected to differentiation induction treatment, it can also be confirmed whether or not the undifferentiated stem cells maintain an undifferentiated state.
- FOXB2 mRNA of the cells constituting the cell group is detected by the method of the present invention. If FOXB2 mRNA is detected, it is determined that there is a differentiated cell in the sample (the meaning of “differentiated state” is the same as described above; the same applies hereinafter), and if FOXB2 mRNA is not detected What is necessary is just to determine with the cell of the state differentiated to the sample not existing. Alternatively, the expression of FOXB2 protein is detected, and if FOXB2 protein is detected, it is determined that there is a differentiated cell in the sample, and if FOXB2 protein is not detected, the differentiated cell is detected in the sample. What is necessary is just to determine that it does not exist.
- the method of the present invention can be applied to quality control of undifferentiated stem cells.
- the medium does not contain, for example, a differentiation-inducing factor and maintains the undifferentiated state of undifferentiated cells.
- the medium must be able to be cultured as it is. If the method for determining a differentiation state of the present invention is used, a quality inspection of such a medium can be performed.
- the medium can be cultured while maintaining the undifferentiated state of the stem cells.
- the medium is a medium that can be cultured while maintaining the undifferentiated state of the stem cells.
- Differentiated cells can be prepared / isolated by applying the method of the present invention.
- differentiated cells of anti-FOXB2 protein antibody labeled with a labeling substance according to “1) Method of detecting without destroying cells” described in “(2) Method of detecting FOXB2 protein expression” above.
- Cells can be prepared and isolated by reacting with or expected to contain cells, and then separating and purifying only fluorescently labeled cells by a method such as flow cytometry.
- undifferentiated stem cells can be prepared and isolated by separating and producing only cells that are not fluorescently labeled by a method such as flow cytometry in the same manner as described above.
- the present invention can be applied to a method for confirming whether a substance has the ability to induce differentiation of undifferentiated stem cells.
- the differentiation marker of the present invention examples include “a differentiation marker selected from mRNA or protein derived from FOXB2 gene”. Specifically, the differentiation marker of the present invention is a differentiation marker for stem cells. Specific examples of the stem cells are as described above.
- FOXB2 gene-derived mRNA or protein examples include the FOXB2 mRNA and FOXB2 protein according to the present invention described above. Specific examples thereof are as described above.
- differentiation markers selected from the following (i) to (vii) can be mentioned.
- (Iii) mRNA encoding the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 35 (Iv) Amino acids in which 1 to several, preferably 1 to 5, more preferably 1 to 3 amino acids of the amino acid sequence represented by SEQ ID NO: 2 or 35 are deleted, inserted, substituted or added MRNA encoding sequence (V) mRNA encoding an amino acid sequence having a sequence homology of 70%, preferably 80%, more preferably 95%, and still more preferably 97% or more with the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 35 (V
- kits for Differentiating State Determination examples include a kit equipped with a reagent for detecting the expression of the FOXB2 gene, or a kit equipped with a reagent for measuring the expression level of the FOXB2 gene.
- Kits provided with primers used for detecting the expression of FOXB2 mRNA or measuring the expression level thereof, or labels thereof (b) The expression of FOXB2 protein is detected or the expression level is determined.
- Kit comprising an antibody against FOXB2 protein used for measurement (an antibody that recognizes FOXB2 protein, preferably an antibody that specifically binds to FOXB2 protein) or a label of the antibody
- Examples of the “primer used for detecting the expression of FOXB2 mRNA or measuring the expression level” according to the above (a) include, for example, “the nucleotide sequence represented by SEQ ID NO: 1 or SEQ ID NO: 34” A primer used for detecting the partial sequence ”.
- a-1) a primer pair used when PCR is performed using the cDNA obtained by the reverse transcription reaction as a template
- a-2 A combination of an amplification primer used for the reverse transcription reaction and a primer pair used for performing PCR using the cDNA obtained by the reverse transcription reaction as a template.
- At least one of the primers constituting the primer pair (a-1) may be labeled with a labeling substance as necessary.
- Specific examples of the primer pair (a-1) include “a primer pair of a primer having the base sequence represented by SEQ ID NO: 9 and a primer having the base sequence represented by SEQ ID NO: 10” or “SEQ ID NO: 45 And a primer pair of a primer having the base sequence represented by SEQ ID NO: 46 and a primer having the base sequence represented by SEQ ID NO: 46.
- a primer comprising a primer represented by SEQ ID NO: 4, a primer having a base sequence represented by SEQ ID NO: 9 and a primer having a base sequence represented by SEQ ID NO: 10
- a primer pair of a primer represented by SEQ ID NO: 37, a primer having the base sequence represented by SEQ ID NO: 45 and a primer having the base sequence represented by SEQ ID NO: 46, Combination a primer comprising a primer represented by SEQ ID NO: 4, a primer having a base sequence represented by SEQ ID NO: 9 and a primer having a base sequence represented by SEQ ID NO: 10
- an antibody against a protein having the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 35 can be mentioned.
- the kit containing (a-1) or (a-2) as a constituent element further includes a reverse transcriptase used for the RT-PCR method and, if necessary, a nucleic acid synthase (DNA polymerase, RNA polymerase, etc.) Further, it may contain a substrate (dNTP, rNTP, etc.) according to the enzyme, a double-stranded intercalator (SYBR TM Green, ethidium bromide, etc.) or a labeled detection substance such as FAM or TAMRA.
- the kit containing the above (a-1) or (a-2) as a constituent element is, for example, a buffer, a stabilizer, a preservative, etc., and does not inhibit the stability of coexisting reagents, Those that do not inhibit PCR or hybridization reaction may be included.
- the concentration may be appropriately selected from a concentration range usually used in this field.
- the buffer include, for example, Tris buffer, phosphate buffer, veronal buffer, borate buffer, Good buffer, and the like buffers used for carrying out normal PCR and hybridization reactions. All liquids are listed.
- the pH is not particularly limited, and examples thereof include a range of 5 to 9.
- reagents included in the kit containing the above (b) as a constituent reagents usually used in this field, such as buffers, sensitizers, surfactants, preservatives (for example, sodium azide, salicylic acid, benzoic acid) Acid, etc.), stabilizers (eg albumin, globulin, water-soluble gelatin, surfactants, saccharides, etc.), activators, coexisting substance avoidance agents, and other reagents used in this field. That do not inhibit the stability and antigen-antibody reaction.
- concentration range of these reagents and the like may be appropriately selected from the concentration ranges usually used in the measurement method known per se. Specific examples of the buffer and the like, the pH and concentration thereof are as described above.
- kits for determining the differentiation state of cells according to the present invention include suspensions or the like suspended in appropriate buffers. It may be in a solution state, or a frozen product obtained by freezing it or a freeze-dried product obtained by freeze-drying. Specific examples of the buffering agent used for this purpose, the pH and the concentration thereof are as described above.
- the kit of the present invention includes instructions for use in a method for detecting FOXB2 gene expression (eg, FOXB2 mRNA expression or FOXB2 protein expression) of the stem cells according to the present invention, or differentiation of the cells of the present invention. Instructions for carrying out the method for determining the state may be included.
- the “instructions” are the instruction manuals, package inserts, pamphlets (leaflets), etc. of the kits in which the features, principles, operation procedures, judgment procedures, etc. of the method are substantially described in text or diagrams. Means.
- Example 1 Expression of FOXB2 mRNA and a known undifferentiated marker of the hiPS cells subjected to differentiation induction was detected by RT-PCR.
- hiPS cells 201B7 strain, iPS Cell Research Institute, Kyoto University (iPS Academia Japan Ltd.)
- differentiated cells HDF cells (human normal cell-derived fibroblasts) , Lonza Japan Co., Ltd.) was subcultured 3 times in a medium (StemSure hPSC Medium, Wako Pure Chemical Industries, Ltd.) with or without bFGF (cells on day 5).
- a medium StemSure hPSC Medium, Wako Pure Chemical Industries, Ltd.
- binding buffer 5.5 M guanidine hydrochloride (manufactured by Wako Pure Chemical Industries, Ltd.), 20 mM Tris-HCl pH6.6
- Econospin sica membrane spin column for nucleic acid purification
- the product was transferred to Gene Design Co., Ltd. and centrifuged at 12000 ⁇ g at room temperature for 1 minute to remove the tube solution.
- wash Buffer 2 mM Tris-HCl pH 7.5 (Nippon Gene), 80% ethanol (Wako Pure Chemical Industries, Ltd.)
- FOXB2 mRNA amplification primer CAGAAGCTACCCTTGCCAG (SEQ ID NO: 4, GenBank Accession No. NM_001013735: 242-260 (corresponds to the base sequence of the complementary strand of the 242-260th base sequence of the base sequence of GenBank Accession No. NM_001013735) the same.)
- -OCT3 / 4 mRNA amplification primer GTTCTTGAAGCTAAGCTGCAG (SEQ ID NO: 5, GenBank Accession No. NM_002701: 641-661)
- ⁇ SOX2 amplification primers mRNA GACCACACCATGAAGGCATTC (SEQ ID NO: 7, GenBank Accession No. NM_003106: 572-592 ), GAPDH mRNA amplification primer, GTCTACATGGCAACTGTGAGG (SEQ ID NO: 8, GenBank Accession No. NM_002046: 1303-1323) (GAPDH: glyceraldehyde-3-phosphate dehydrogenase)
- Binding Buffer 5.5 M guanidine hydrochloride (Wako Pure Chemical Industries, Ltd.), 20 mM Tris-HCl pH 6.6 (Wako Pure Chemical Industries, Ltd.)
- Econospin nucleic acid purification
- RTase ReverTra Ace (manufactured by Toyobo Co., Ltd.), reverse transcriptase) is not added. Reaction was performed.
- the base sequence of each primer used is as follows. The following primers are all manufactured by Sigma-Aldrich.
- the FOXB2 gene (base sequence represented by SEQ ID NO: 1), the 45th to 223rd, 179 bp region (SEQ ID NO: 3) (GenBank Accession No. NM_001013735.1) position 45-223) is amplified.
- NANOG cDNA GenBank Accession No. NM_024865: 284-305, 528-550
- Forward primer CACCTATGCCTGTGATTTGTGG (SEQ ID NO: 13)
- Reverse primer CATTGAGTACACACAGCTGGGTG (SEQ ID NO: 14)
- Amplification chain length 267bp
- GAPDH cDNA GenBank Accession No.NM_002046: 240-260, 618-638
- Forward primer GTCACCAGGGCTGCTTTTAAC (SEQ ID NO: 17)
- Reverse primer GGCATTGCTGATGATCTTGAG (SEQ ID NO: 18)
- Amplification chain length 399bp
- OCT3 / 4 mRNA (FIG. 1 (3)), NANOG mRNA (FIG. 1 (4)) and SOX2 mRNA (FIG. 5)) was expressed in hiPS cells (in the case of hiPS / bFGF (+) / RTase (+)) in an undifferentiated / pluripotent state.
- expression was still occurring (a band was confirmed) in the hiPS cells (in the case of hiPS / bFGF ( ⁇ ) / RTase (+)) 5 days after differentiation induction treatment.
- OCT3 / 4 mRNA, NANOG mRNA and SOX2 mRNA were not expressed in HDF cells, which are differentiated cells.
- FOXB2 mRNA (Fig. 1 (1)) is expressed in hiPS cells (in the case of hiPS / bFGF (-) / RTase (+)) 5 days after differentiation induction treatment (a band was confirmed). It was confirmed. However, FOXB2 mRNA is expressed in hiPS cells (in the case of hiPS / bFGF (+) / RTase (+)) that are still undifferentiated / pluripotent and in differentiated cells (particularly cells that have been differentiated). It was not expressed in some HDF cells.
- Fig. 1 (2) show that “hiPS ⁇ bFGF (+) ⁇ RTase (+)”, “hiPS ⁇ bFGF ( ⁇ ) ⁇ RTase (+)”, “HDF ⁇ RTase In the case of (+), the band is confirmed.
- hiPS • bFGF (+) • RTase ( ⁇ ) “hiPS • bFGF ( ⁇ ) • RTase ( ⁇ )”
- DF • RTase ( ⁇ ) No band was confirmed. This confirmed that mRNA was not degraded in this experimental system.
- FOXB2 mRNA differentiation marker by detecting the FOXB2 mRNA, it was revealed that it is possible to determine the differentiation state of a cell. Further, since the commonly measured in undifferentiated markers are (OCT3 / 4, NANOG, SOX2 ) significantly FOXB2 mRNA expression even at a stage where the change has not been detected in the expression is detected, FOXB2 mRNA is conventionally It was found that the differentiation state of the cells can be determined at an earlier stage of differentiation than the undifferentiated marker.
- Example 2 Stem cell culture and differentiation induction treatment HiPS cells (201B7 strain, iPS Cell Laboratory, Kyoto University (iPS Academia Japan)) with or without bFGF (StemSure hPSC Medium, Wako Pure Chemical Industries, Ltd.) And cells were collected on the 3rd, 5th, and 7th days of culture.
- HiPS cells 201B7 strain, iPS Cell Laboratory, Kyoto University (iPS Academia Japan)
- bFGF StemSure hPSC Medium, Wako Pure Chemical Industries, Ltd.
- HDF cells human normal cell-derived fibroblasts, manufactured by Lonza Japan Co., Ltd.
- MEM medium (+ 10% FBS) manufactured by Wako Pure Chemical Industries, Ltd.
- HMSC-bm cells human bone marrow-derived mesenchymal stem cells
- TOTAL RNA manufactured by ScienCell Research Laboratories
- -FOXB2 mRNA amplification primer CAGAAGCTACCCTTGCCAG (SEQ ID NO: 4, GenBank Accession No. NM_001013735: 242-260), -OCT3 / 4 mRNA amplification primer, GTTCTTGAAGCTAAGCTGCAG (SEQ ID NO: 5, GenBank Accession No. NM_002701: 641-661), ⁇ NANOG amplification primers mRNA, GTTCTGGAACCAGGTCTTCAC (SEQ ID NO: 6, GenBank Accession No. NM_024865: 631-651 ), ⁇ SOX2 amplification primers mRNA, GACCACACCATGAAGGCATTC (SEQ ID NO: 7, GenBank Accession No. NM_003106: 572-592 ), GAPDH mRNA amplification primer, GTCTACATGGCAACTGTGAGG (SEQ ID NO: 8, GenBank Accession No. NM_002046: 1303-1323)
- PCR reaction 1 ⁇ L of cDNA obtained in (4) above, 5 ⁇ L of distilled water, 2 ⁇ PCR Buffer for KOD FX Neo (Toyobo Co., Ltd.) 12.5 ⁇ L, 2 mM dNTPs (Toyobo Co., Ltd.) 4 ⁇ L, KOD FX Neo (manufactured by Toyobo Co., Ltd.) 0.5 ⁇ L (0.5 U), 1 ⁇ L of each forward primer (10 ⁇ M) and 1 ⁇ L of each reverse primer (10 ⁇ M) were mixed.
- KOD FX Neo manufactured by Toyobo Co., Ltd.
- the base sequence of each Primer used is as follows. The following primers are all manufactured by Sigma-Aldrich.
- NANOG cDNA GenBank Accession No. NM_024865: 284-305, 528-550
- Forward primer CACCTATGCCTGTGATTTGTGG (SEQ ID NO: 13)
- Reverse primer CATTGAGTACACACAGCTGGGTG (SEQ ID NO: 14)
- Amplification chain length 267bp
- GAPDH cDNA GenBank Accession No.NM_002046: 240-260, 618-638
- Forward primer GTCACCAGGGCTGCTTTTAAC (SEQ ID NO: 17)
- Reverse primer GGCATTGCTGATGATCTTGAG (SEQ ID NO: 18)
- Amplification chain length 399bp
- Electrophoresis 5 ⁇ L of PCR amplification product and 1 ⁇ L of 6 ⁇ Loading Buffer Double Dye (manufactured by Nippon Gene Co., Ltd.) were mixed and electrophoresed on a 1.5% agarose gel. Staining was performed with GelRed Nucleic Acid Gel Stain (Wako Pure Chemical Industries, Ltd.).
- known undifferentiation markers OCT3 / 4 mRNA, NANOG mRNA, SOX2 mRNA, GAPDH mRNA
- FOXB2 mRNA FOXB2 mRNA
- HMSC-bm human bone marrow-derived mesenchymal stem cells
- FOXB2 mRNA is also expressed in known undifferentiated markers ( OCT3 / 4 mRNA, NANOG mRNA, SOX2 mRNA, GAPDH mRNA). The expression of) was not confirmed.
- HMSC-bm is a somatic stem cell formed from a stem cell (RS cell) through a mesoderm. From this, it can be inferred that if differentiation of undifferentiated stem cells proceeds to this level, FOXB2 mRNA is not expressed, in other words, FOXB2 mRNA is specifically expressed in the early stage of cell differentiation.
- FOXB2 mRNA and the expression of known undifferentiated markers were not confirmed in the HDF cells on day 5 of culture.
- FOXB2 mRNA was detected earlier than the change in the expression of undifferentiated markers ( OCT3 / 4 , NANOG , SOX2 ) which were generally measured. This indicates that FOXB2 mRNA is particularly useful as a differentiation marker in the early stages of cell differentiation.In other words, FOXB2 mRNA is detected at the initial stage of differentiation by detecting the expression of FOXB2 mRNA. It has become clear that you can.
- FIG. 1 Stem cell culture and differentiation induction treatment hiPS cells (201B7 strain, iPS Cell Research Institute, Kyoto University (iPS Academia Japan Ltd.)) and, as a comparison, differentiated cells, HDF cells (human normal cell-derived fibroblasts) , Lonza Japan Co., Ltd.) was subcultured 3 times in a medium (StemSure hPSC Medium, manufactured by Wako Pure Chemical Industries, Ltd.) with or without bFGF (cells on day 6). was recovered.
- a medium Stem cell culture and differentiation induction treatment hiPS cells (201B7 strain, iPS Cell Research Institute, Kyoto University (iPS Academia Japan Ltd.)
- differentiated cells human normal cell-derived fibroblasts
- RNA was extracted from the cells recovered in (1) above using a commercially available nucleic acid extraction reagent kit ISOGEN (manufactured by Nippon Gene Co., Ltd.) according to the instruction manual.
- NM_002701: 641-661 ⁇ NANOG mRNA amplification primer, GTTCTGGAACCAGGTCTTCAC (SEQ ID NO: 6, GenBank Accession No. NM_024865: 631-651) ⁇ SOX2 mRNA amplification primers, GACCACACCATGAAGGCATTC (SEQ ID NO: 7, GenBank Accession No. NM_003106: 572-592 ) FGF5 mRNA amplification primer, CTCCCTGAACTTGCAGTCATC (SEQ ID NO: 19, GenBank Accession No. NM_004464: 709-729) CDX2 mRNA amplification primer, CCTGAGGAGTCTAGCAGAGTC (SEQ ID NO: 20, GenBank Accession No.
- GATA4 mRNA amplification primers GATTACGCAGTGATTATGTCCC (SEQ ID NO: 21, GenBank Accession No. NM_001308094: 1110-1131 )
- Amplification primer for GATA6 mRNA CATCTTGACCCGAATACTTGAG (SEQ ID NO: 22, GenBank Accession No. NM_005257: 1961-1982)
- SOX17 mRNA amplification primers CCCAGGAGTCTGAGGATTTCC (SEQ ID NO: 23, GenBank Accession No. NM_022454: 1515-1535 )
- GAPDH mRNA GTCTACATGGCAACTGTGAGG (SEQ ID NO: 8, GenBank Accession No. NM_002046: 1303-1323 )
- Binding Buffer 5.5 M guanidine hydrochloride (Wako Pure Chemical Industries, Ltd.), 20 mM Tris-HCl pH 6.6 (Wako Pure Chemical Industries, Ltd.)
- Econospin ((Co)
- 500 ⁇ L of Wash Buffer (2 mM Tris-HCl pH 7.5 (Nippon Gene Co., Ltd.), 80% ethanol (Wako Pure Chemical Industries, Ltd.) was added, and centrifuged at 12000 ⁇ g for 1 minute at room temperature.
- PCR reaction 1 ⁇ L of cDNA obtained in (4) above, 5 ⁇ L of distilled water, 2 ⁇ PCR Buffer for KOD FX Neo (Toyobo Co., Ltd.) 12.5 ⁇ L, 2 mM dNTPs (Toyobo Co., Ltd.) 4 ⁇ L, KOD FX Neo (manufactured by Toyobo Co., Ltd.) 0.5 ⁇ L (0.5 U), 1 ⁇ L of each forward primer (10 ⁇ M) and 1 ⁇ L of each reverse primer (10 ⁇ M) were mixed.
- KOD FX Neo manufactured by Toyobo Co., Ltd.
- the base sequence of each Primer used is as follows. The following primers are all manufactured by Sigma-Aldrich.
- NANOG cDNA GenBank Accession No. NM_024865: 284-305, 528-550
- Forward primer CACCTATGCCTGTGATTTGTGG (SEQ ID NO: 13)
- Reverse primer CATTGAGTACACACAGCTGGGTG (SEQ ID NO: 14)
- Amplification chain length 267bp
- FGF5 cDNA GenBank Accession No.NM_004464: 462-482, 615-637
- Forward primer GCAGAGCAGTTTCCAGTGGAG (SEQ ID NO: 24)
- Reverse primer GTATTCCTACAATCCCCTGAGAC (SEQ ID NO: 25)
- Amplified chain length 176 bp
- CDX2 cDNA GenBank Accession No. NM_001265: 923-944, 1176-1196
- Forward primer CAAATATCGAGTGGTGTACACG (SEQ ID NO: 26)
- Reverse primer GACACTTCTCAGAGGACCTGG (SEQ ID NO: 27) Amplified chain length: 274bp
- GATA4 cDNA GenBank Accession No. NM_001308094: 795-816, 1020-1040
- Forward primer CAGCTCCTTCAGGCAGTGAGAG (SEQ ID NO: 28)
- Reverse primer CGGGAGACGCATAGCCTTGTG (SEQ ID NO: 29)
- Amplified chain length 246 bp
- GATA6 cDNA GenBank Accession No. NM_005257: 1682-1703, 1842-1864
- Forward primer GCTTGTGGACTCTACATGAAAC (SEQ ID NO: 30)
- Reverse primer GCTGCAATCATCTGAGTTAGAAG (SEQ ID NO: 31)
- Amplification chain length 183 bp
- GAPDH cDNA GenBank Accession No.NM_002046: 240-260, 618-638
- Forward primer GTCACCAGGGCTGCTTTTAAC (SEQ ID NO: 17)
- Reverse primer GGCATTGCTGATGATCTTGAG (SEQ ID NO: 18)
- Amplification chain length 399bp
- FGF5 mRNA ectodermal differentiation marker
- CDX2 mRNA ectodermal differentiation marker
- GATA4 mRNA endodermal differentiation marker
- GATA6 mRNA endodermal differentiation marker
- SOX7 mRNA endodermal differentiation
- FOXB2 mRNA was confirmed to be expressed (a band was confirmed) in hiPS cells (in the case of hiPS • bFGF ( ⁇ ) • RTase (+)) on the 6th day after differentiation induction treatment.
- the GAPDH mRNA detection results show that “hiPS • bFGF (+) • RTase (+)”, “hiPS • bFGF ( ⁇ ) • RTase (+)”, “HDF • RTase (+)” A band was confirmed, and no band was confirmed for “hiPS • bFGF (+) • RTase ( ⁇ )”, “hiPS • bFGF ( ⁇ ) • RTase ( ⁇ )”, “DF • RTase ( ⁇ )”. . This confirmed that mRNA was not degraded in this experimental system.
- FOXB2 mRNA differentiation marker by detecting the FOXB2 mRNA, it was revealed that it is possible to determine the differentiation state of a cell.
- FOXB2 mRNA expression was remarkably detected even when changes in the expression of general undifferentiated markers ( OCT3 / 4 , NANOG , SOX2 ) were not detected.
- FOXB2 mRNA expression was detected at the stage where FGF5 mRNA, which is known as the most promising differentiation marker, has not yet been expressed. That is, it was found that FOXB2 mRNA can determine the differentiation state of cells at an earlier stage of differentiation (initial stage) than conventional differentiation markers and undifferentiation markers.
- FOXB2 mRNA is a very useful differentiation marker compared to conventional differentiation / undifferentiation markers.
- differentiated cells can be determined at the early stage of culture, it is useful for early screening of cells, quality control of stem cells, and the like, and shortening of the culture period and cost reduction of the medium cost can be expected.
- Example 4 Mouse ES cells were cultured in a LIF-free medium and subjected to differentiation induction, and expression of FOXB2 mRNA and a known undifferentiated marker was detected by RT-PCR.
- Stem cell culture and differentiation induction treatment mES cells (D3 strain, ATCC, b723512), LIF added (1000Unit) or non-added medium (StemSure DMEM, StemSure Serum replacement, MEM non-essential amino acid solution, L-glutamine solution , StemSure 2-mercaptoethanol solution, manufactured by Wako Pure Chemical Industries, Ltd.) and subcultured three times, and cells were collected on the 3rd, 5th, and 7th days of culture.
- mES cells D3 strain, ATCC, b723512
- LIF added 1000Unit
- non-added medium StemSure DMEM, StemSure Serum replacement, MEM non-essential amino acid solution, L-glutamine solution , StemSure 2-mercaptoethanol solution, manufactured by Wako Pure Chemical Industries, Ltd.
- RNA was extracted from the cells recovered in (1) above using a commercially available nucleic acid extraction reagent kit ISOGEN (manufactured by Nippon Gene Co., Ltd.) according to the instruction manual.
- binding buffer 5.5 M guanidine hydrochloride (manufactured by Wako Pure Chemical Industries, Ltd.), 20 mM Tris-HCl pH6.6
- Econospin sica membrane spin column for nucleic acid purification
- RNA was recovered by centrifugation at 12000 ⁇ g, room temperature for 1 minute, followed by ethanol precipitation, and the resulting precipitate was dissolved in 9.5 ⁇ L of distilled water. .
- NM_008452: 1205-1227 -Esrrb mRNA amplification primer, GATTCGAGACGATCTTAGTCAATG (SEQ ID NO: 42, GenBank Accession No. NM_011934: 957-980) -Fgf5 mRNA amplification primer, GACGCATAGGTATTATAGCTG (SEQ ID NO: 43, GenBank Accession No. NM_010203: 729-749) -Gapdh mRNA amplification primer, CTTGATGTCATCATACTTGGC (SEQ ID NO: 44, GenBank Accession No. NM_001289726: 843-863)
- Binding Buffer 5.5 M guanidine hydrochloride (Wako Pure Chemical Industries, Ltd.), 20 mM Tris-HCl pH 6.6 (Wako Pure Chemical Industries, Ltd.) was added and mixed, and Econospin (Corporation)
- the tube solution was removed by centrifugation at 12000 ⁇ g and room temperature for 1 minute, and then washed Buffer (2 mM Tris-HCl pH 7.5 (Nippon Gene Co., Ltd.), 80% ethanol ( 500 ⁇ L of Wako Pure Chemical Industries, Ltd.) was added, centrifuged at 12000 ⁇ g, room temperature for 1 minute to remove the tube solution, and then further centrifuged at 12000 ⁇ g, room temperature for 1 minute.
- PCR reaction 1 ⁇ L of cDNA obtained in (4) above, 5 ⁇ L of distilled water, 2 ⁇ PCR Buffer for KOD FX Neo (Toyobo Co., Ltd.) 12.5 ⁇ L, 2 mM dNTPs (Toyobo Co., Ltd.) 4 ⁇ L, KOD FX Neo (manufactured by Toyobo Co., Ltd.) 0.5 ⁇ L (0.5 U), 1 ⁇ L of each forward primer (10 ⁇ M) and 1 ⁇ L of each reverse primer (10 ⁇ M) were mixed.
- the base sequence of each Primer used is as follows. The following primers are all manufactured by Sigma-Aldrich.
- Sox2 cDNA GenBank Accession No. NM_011443: 1652-1674, 1836-1859
- Forward primer GAATCGGACCATGTATAGATCTG (SEQ ID NO: 51)
- Reverse primer CATTTGATTGCCATGTTTATCTCG (SEQ ID NO: 52)
- Amplification chain length 208bp
- Fgf5 cDNA GenBank Accession No. NM_010203: 445-465, 617-639
- Forward primer GAACATAGCAGTTTCCAGTGG (SEQ ID NO: 57)
- Reverse primer GTTGCTGAAAACTCCTCGTATTC (SEQ ID NO: 58)
- Amplification chain length 195bp
- Gapdh cDNA GenBank Accession No.NM_001289726: 224-246, 512-534 Forward primer: GTTCCAGTATGACTCCACTCACG (SEQ ID NO: 59) Reverse primer: CATTGCTGACAATCTTGAGTGAG (SEQ ID NO: 60) Amplification chain length: 311bp
- FOXB2 mRNA is expressed (a band was confirmed) in ES cells (in the case of LIF (-) / RTase (+)) 7 days after differentiation induction treatment. confirmed. However, FOXB2 mRNA was not expressed in ES cells (in the case of LIF (+) / RTase (+)) maintaining undifferentiated / pluripotency.
- Fgf5 mRNA which is a differentiation marker, was expressed in ES cells (in the case of LIF ( ⁇ ) / RTase (+)) 7 days after differentiation induction treatment (a band was confirmed).
- undifferentiated markers OCT3 / 4 mRNA, NANOG mRNA, and SOX2 mRNA are expressed in ES cells (in the case of LIF (+) / RTase (+)) that maintain undifferentiated / pluripotent. It was. In addition, it was confirmed that the cells were still expressed (a band was confirmed) in the ES cells (in the case of LIF ( ⁇ ) / RTase (+)) 7 days after the differentiation induction treatment.
- FOXB2 mRNA expression was detected as early as Fgf5 mRNA, which is currently considered the most promising as a differentiation marker.
- FOXB2 mRNA expression was remarkably detected even when changes in the expression of general undifferentiated markers ( OCT3 / 4 , NANOG , SOX2 ) were not detected.
- the expression of FOXB2 mRNA was confirmed at the stage of 7 days after induction of differentiation where Klf2 mRNA and Esrrb mRNA, which are known as naive markers, have not yet disappeared.
- FOXB2 mRNA can determine the differentiation state of ES cells at an earlier stage of differentiation than conventional undifferentiated markers.
- it is possible to determine the differentiated cells at the early stage of culture it is useful for early screening of cells, quality control of stem cells, and the like, and shortening of the culture period and cost reduction of the medium cost can be expected.
- HiPS cells were seeded in 4 wells so that the concentration of hPSC ⁇ medium (manufactured by Wako Pure Chemical Industries, Ltd.) with or without the addition of + bFGF and + ROCKtorinhibitor was 20000 cells / well and cultured for 1 day.
- FIG. 5 (1) is a photograph of hiPS cells cultured in a bFGF-free medium (differentiation induction treatment). (2) is a photograph of hiPS cells cultured in a bFGF-added medium.
- the fraction after electrophoresis is transferred to a PVDF membrane by a semi-driving method.
- Block Ace (DS Pharma Biomedical Co., Ltd.) is dissolved in PBS-T (Phosphate Buffered Saline with Tween TM 20, pH 7.4) to obtain a blocking solution.
- PBS-T Phosphate Buffered Saline with Tween TM 20, pH 7.4
- the PVDF membrane after the transfer is immersed in this blocking solution and subjected to blocking treatment at room temperature for 1 hour, and then the PVDF membrane is washed and immersed in the blocking solution.
- the peroxidase-labeled anti-human FOXB2 protein antibody obtained in 2) above is added to the blocking solution and immersed at room temperature for about 1 hour.
- the PVDF membrane is washed, luminescence is generated with ECL TM Prime Western Blotting Detection Reagent (peroxidase chemiluminescence substrate, manufactured by GE Healthcare), and detection is performed with an exposure time of 10 seconds using LAS4000 (manufactured by FUJIFILM Corporation).
- ECL TM Prime Western Blotting Detection Reagent peroxidase chemiluminescence substrate, manufactured by GE Healthcare
- detection is performed with an exposure time of 10 seconds using LAS4000 (manufactured by FUJIFILM Corporation).
- the differentiation state of stem cells can be determined at the initial stage of differentiation.
- the present invention can also be applied to stem cell quality control and differentiated cell preparation / isolation methods. Furthermore, since the present invention can determine differentiated cells at the early stage of culture, it is useful for early screening of cells and quality control of stem cells, and can be expected to shorten the culture period and reduce the cost of the medium.
Abstract
Description
(1)幹細胞のFOXB2遺伝子の発現を検出し、その結果に基づいて判定を行う、細胞の分化状態の判定方法。
(2)FOXB2遺伝子由来のmRNA又は蛋白質から選択される、分化マーカー。
・配列番号1で表される塩基配列(GenBank Accession No. NM_001013735)を有するmRNA
・配列番号1で表される塩基配列と70%、好ましくは80%、より好ましくは95%更により好ましくは97%以上の配列相同性を有する塩基配列を有するmRNA
・配列番号2で表されるアミノ酸配列をコードするmRNA
・配列番号2で表されるアミノ酸配列の1~数個、好ましくは1~5個、より好ましくは1~3個のアミノ酸が欠失、挿入、付加、あるいは置換されたアミノ酸配列をコードするmRNA
・配列番号2で表されるアミノ酸配列と70%、好ましくは80%、より好ましくは95%、更により好ましくは97%以上の配列相同性を有するアミノ酸配列をコードするmRNA。
・配列番号34で表される塩基配列(GenBank Accession No. NM_008023)を有するmRNA
・配列番号34で表される塩基配列と70%、好ましくは80%、より好ましくは95%、更により好ましくは97%以上の配列相同性を有する塩基配列を有するmRNA
・配列番号35で表されるアミノ酸配列をコードするmRNA
・配列番号35で表されるアミノ酸配列の1~数個、好ましくは1~5個、より好ましくは1~3個のアミノ酸が欠失、挿入、付加、あるいは置換されたアミノ酸配列をコードするmRNA
・配列番号2で表されるアミノ酸配列と70%、好ましくは80%、より好ましくは95%、更により好ましくは97%以上の配列相同性を有するアミノ酸配列をコードするmRNA
・配列番号2で表されるアミノ酸配列又はその1個若しくは数個、好ましくは1~5個、より好ましくは1~3個のアミノ酸が欠失、置換、若しくは付加されたアミノ酸配列を有するもの
・配列番号2で表されるアミノ酸配列と70%、好ましくは80%、より好ましくは95%、更により好ましくは97%以上の配列相同性を有するアミノ酸配列を有するもの
・配列番号35で表されるアミノ酸配列又はその1個若しくは数個、好ましくは1~5個、より好ましくは1~3個のアミノ酸が欠失、置換、若しくは付加されたアミノ酸配列を有するもの
・配列番号35で表されるアミノ酸配列と70%、好ましくは80%、より好ましくは95%、更により好ましくは97%以上の配列相同性を有するアミノ酸配列を有するもの
本発明の細胞の分化状態の判定方法は、「幹細胞のFOXB2遺伝子の発現を検出し、その結果に基づいて判定を行う、細胞の分化状態の判定方法。」である。
FOXB2遺伝子の発現を検出する方法としては、FOXB2 mRNAの発現を検出する方法、又はFOXB2蛋白質の発現を検出する方法が挙げられる。
FOXB2 mRNAの発現を検出する方法は、自体公知のmRNAを検出する方法であれば特に制限されず、公知の方法から適宜選択すればよい。
RT-PCR法とは、標的のFOXB2遺伝子(例えばFOXB2 mRNA)を鋳型とし、逆転写反応によりcDNAを合成後、PCRによるDNAの増幅を行う方法〔Kawasaki, E. S., et al., Amplification of RNA. In PCR Protocol, A Guide to methods and applications, Academic Press, Inc., SanDiego, 21-27 (1991)]である。逆転写反応及びDNAの増幅反応の条件は特に限定されるものではなく、適宜最適な条件を採用することができる。また、当該標的の遺伝子(例えばFOXB2 mRNA)の増幅領域は、必ずしも全長である必要はなく、増幅産物の確認に支障が無ければ、当該遺伝子の一部領域であってもよい。増幅されたcDNA量(mRNA量に相当する)は、例えば、上記DNA増幅反応液を電気泳動に供した後、目的増幅断片に特異的にハイブリダイズするプローブを用いることで検出すればよい。
ノーザンハイブリダイゼーション法よりFOXB2 mRNAを検出する方法としては、例えば、被検細胞から抽出・分離したmRNAを適当な担体に固定し、これとFOXB2 mRNAに相補的な塩基配列を有する標識プローブ(cDNAでもよい)とハイブリダイゼーションを行い、その程度を検出することにより、被検細胞のFOXB2 mRNAを検出する方法が挙げられる。ここで使用するプローブは、FOXB2 mRNAの塩基配列の相補配列の全部からなるものであっても、その一部の塩基配列からなるものであってもよい。また、この検出法に、該プローブを固定化したマイクロアレイ、DNAチップを用いることもできる。
1)細胞を破壊しないで検出する方法
FOXB2 蛋白質は転写因子であるので、細胞の核内に存在する。
また、細胞を破壊する以下の方法を行って、FOXB2蛋白質を検出することもできる。
上記の方法により幹細胞のFOXB2遺伝子の発現を検出して得られた結果に基づいて、被検細胞の分化状態を判定する。
(1)FOXB2 mRNAの発現を検出した結果に基づいて判定する方法
FOXB2 mRNAを検出した結果に基づいて判定する方法としては、例えば以下の方法が挙げられる。
1)上記方法により被検細胞のFOXB2 mRNAの検出を行って、FOXB2 mRNAが検出された場合に、その被検細胞は分化した状態である、と判定される。
FOXB2蛋白質を検出した結果に基づいて判定する方法としては、例えば以下の方法が挙げられる。
1)上記方法により被検細胞のFOXB2蛋白質の検出を行って、FOXB2蛋白質が検出された場合に、その細胞が分化した状態である、と判定される。
本発明の細胞の分化状態の判定方法は、更に以下の方法に応用することができる。
ある細胞群を含有する試料に対して、本発明の方法により細胞群を構成する細胞のFOXB2 mRNAを検出する。そして、FOXB2 mRNAが検出された場合にはその試料に分化した状態の細胞(「分化した状態」の意味は前記した通り。以下同じ。)が存在すると判定し、FOXB2 mRNAが検出されない場合にはその試料に分化した状態の細胞が存在しないと判定すればよい。又は、FOXB2蛋白質の発現を検出し、FOXB2蛋白質が検出された場合にはその試料に分化した状態の細胞が存在すると判定し、FOXB2蛋白質が検出されない場合にはその試料に分化した状態の細胞が存在しないと判定すればよい。
公知の分化誘導処理を施した幹細胞に対して本発明の方法によりFOXB2遺伝子の発現を検出する(FOXB2 mRNA又はFOXB2蛋白質を検出する)ことにより、当該細胞が分化した状態にあるか、又は未分化幹細胞が混入している状態かを判定できる。そのため、本発明の方法は分化細胞の品質管理に応用することができる。
未分化幹細胞を、その未分化状態を維持したまま培養するためには、その培地が、例えば分化誘導因子を含まず、未分化細胞の未分化状態を維持したまま培養できる培地である必要がある。本発明の分化状態の判定方法を用いれば、そのような培地の品質検査を行うことができる。
本発明の方法を応用して、分化細胞を調製・単離することができる。
更に、上記と同様の方法で、蛍光標識されていない細胞のみをフローサイトメトリーなどの方法により分離、製製すれば、未分化幹細胞を調製・単離することができる。
本発明を、ある物質が未分化幹細胞の分化誘導能を有するか確認する方法に応用することができる。
<II.本発明の分化マーカー>
(i)配列番号1若しくは配列番号34で表される塩基配列を有するmRNA
(ii)配列番号1若しくは配列番号34で表される塩基配列と70%、好ましくは80%、より好ましくは95%、更により好ましくは97%以上の配列相同性を有する塩基配列を有するmRNA
(iii)配列番号2若しくは配列番号35で表されるアミノ酸配列をコードするmRNA
(iv)配列番号2若しくは配列番号35で表されるアミノ酸配列の1~数個、好ましくは1~5個、より好ましくは1~3個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列をコードするmRNA
(v)配列番号2若しくは配列番号35で表されるアミノ酸配列と70%、好ましくは80%、より好ましくは95%、更により好ましくは97%以上の配列相同性を有するアミノ酸配列をコードするmRNA
(vi)配列番号2若しくは配列番号35で表されるアミノ酸配列又はその1個若しくは数個、好ましくは1~5個、より好ましくは1~3個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を有する蛋白質
(vii)配列番号2若しくは配列番号35で表されるアミノ酸配列と70%、好ましくは80%、より好ましくは95%、更により好ましくは97%以上の配列相同性を有するアミノ酸配列を有する蛋白質
が挙げられる。
本発明に係る細胞の分化状態判定用キットとしては、FOXB2遺伝子の発現を検出する試薬を備えたキット、又はFOXB2遺伝子の発現量を測定する試薬を備えたキットが挙げられる。
(a)FOXB2 mRNAの発現を検出するか又はその発現量を測定するために使用されるプライマー、又はそれらの標識物を備えたキット
(b)FOXB2蛋白質の発現を検出するか又はその発現量を測定するために使用されるFOXB2蛋白質に対する抗体(FOXB2蛋白質を認識する抗体、好ましくはFOXB2蛋白質に特異的に結合する抗体)又は該抗体の標識物等を備えたキット
(a-1)逆転写反応で得られたcDNAを鋳型としてPCRを行う際に用いられるプライマー対、又は
(a-2)逆転写反応に用いられる増幅プライマーと、逆転写反応で得られたcDNAを鋳型としてPCRを行う際に用いられるプライマー対の組合せ、が挙げられる。
(a-1)のプライマー対の具体例としては、「配列番号9で表される塩基配列を有するプライマーと配列番号10で表される塩基配列を有するプライマーとのプライマー対」又は「配列番号45で表される塩基配列を有するプライマーと配列番号46で表される塩基配列を有するプライマーとのプライマー対」が挙げられる。
分化誘導処理したhiPS細胞の、FOXB2 mRNA及び公知の未分化マーカーの発現を、RT-PCR法により検出した。
(1)幹細胞の培養と分化誘導処理
hiPS細胞(201B7株、京都大学iPS 細胞研究所(iPSアカデミアジャパン株式会社))、及び比較として、分化した細胞であるHDF細胞(ヒト正常細胞由来繊維芽細胞、ロンザジャパン(株)製)を、bFGF添加(100ng/mL)又は無添加の培地(StemSure hPSC Medium、和光純薬工業(株)製)で3回継代培養し、培養5日目に細胞を回収した。
市販の核酸抽出試薬であるキットISOGEN(ニッポンジーン製)を用い、現品説明書に従って、上記(1)で回収した細胞から、Total RNAを抽出した。
上記(2)で抽出したTotal RNAの1μgに、全量17μLになるように蒸留水を加え、10X Reaction Buffer(プロメガ(株)製)を2μL、RQ1 RNase-Free DNase(プロメガ(株)製)を1μL(1U)を加え混合し、37℃、20分間インキュベートした。その後、Stop Buffer(20mM EGTA)(プロメガ(株)製)を1μL加え混合し、65℃、10分間インキュベートした。その後、反応物に結合Buffer(5.5Mグアニジン塩酸塩(和光純薬工業(株)製)、20mM Tris-HCl pH6.6)を100μL加え混合した後、エコノスピン(核酸精製用シリカメンブレンスピンカラム、(株)ジーンデザイン製)に移し、12000×g、室温、1分間遠心分離し、チューブの溶液を除去した。次いで、チューブに洗浄Buffer(2mM Tris-HCl pH7.5((株)ニッポンジーン)、80% エタノール(和光純薬工業(株)製))を500μL添加し、12000×g、室温、1分間遠心分離し、チューブの溶液を除去した。更に12000×g、室温、1分間遠心分離した後、エコノスピン(mRNAが結合している)を新しいチューブに交換し、溶出Buffer(10mMTris-HCl pH8.0)(ニッポンジーン(株)製)を50μL添加し、12000×g、室温、1分間遠心分離してTotal RNAを回収した。その後、エタノール沈殿を行い、得られた沈殿物を蒸留水9.5μLに溶解した。
上記(3)でDNase処理したTotal RNA 9.5μLに、下記の各mRNAを標的とする増幅プライマーを含む混合Primer(各5μM)1μLを加えた。下記プライマーは、すべてシグマアルドリッチ社製である。
・OCT3/4 mRNAの増幅プライマー、GTTCTTGAAGCTAAGCTGCAG (配列番号5、GenBank Accession No. NM_002701 : 641-661)、
・NANOG mRNAの増幅プライマー、GTTCTGGAACCAGGTCTTCAC (配列番号6、GenBank Accession No. NM_024865 : 631-651)、
・SOX2 mRNAの増幅プライマー、GACCACACCATGAAGGCATTC (配列番号7、GenBank Accession No. NM_003106 : 572-592)、
・GAPDH mRNAの増幅プライマー、GTCTACATGGCAACTGTGAGG (配列番号8、GenBank Accession No. NM_002046 : 1303-1323)
(GAPDH:グリセルアルデヒド-3-リン酸デヒドロゲナーゼ、glyceraldehyde-3-phosphate dehydrogenase)
上記(4)で得られたcDNA 1μLと、蒸留水5μL、2×PCR Buffer for KOD FX Neo (東洋紡)12.5μL、2 mM dNTPs(東洋紡)4μL、KOD FX Neo(東洋紡)0.5μL(0.5U)、各フォワードプライマー(10μM)1μL、各リバースプライマー(10μM)1μLを混合した。
フォワードプライマー: CTACTCTTACATCTCGCTGACCG(配列番号9)
リバースプライマー: GAATCTTGATGAAGCAGTCGTTG(配列番号10)
増幅鎖長 : 179bp
※配列番号9のフォワードプライマーと配列番号10のリバースプライマーは、それぞれFOXB2 cDNA、GenBank Accession No. NM_001013735の45-67番目の塩基配列及び、201-223番目の塩基配列をもとに設計された。以下同じ。
フォワードプライマー: CTTGGAGACCTCTCAGCCTGAG(配列番号11)
リバースプライマー: CTTCAGGAGCTTGGCAAATTG(配列番号12)
増幅鎖長 : 196bp
フォワードプライマー: CACCTATGCCTGTGATTTGTGG(配列番号13)
リバースプライマー: CATTGAGTACACACAGCTGGGTG(配列番号14)
増幅鎖長 : 267bp
フォワードプライマー: GTATCAGGAGTTGTCAAGGCAGAG(配列番号15)
リバースプライマー: CAGCTCCGTCTCCATCATGTTG(配列番号16)
増幅鎖長 : 434bp
フォワードプライマー: GTCACCAGGGCTGCTTTTAAC(配列番号17)
リバースプライマー: GGCATTGCTGATGATCTTGAG(配列番号18)
増幅鎖長 : 399bp
上記(5)で得られたPCR増幅産物5μLと、6×Loading Buffer Double Dye(ニッポンジーン(株)製)1μLとを混合し、これを1.5%アガロースゲルにて電気泳動した。染色はGelRed核酸ゲル染色液(和光純薬工業(株)製)にて行った。
結果を図1に併せて示す。
(1)幹細胞の培養と分化誘導処理
hiPS細胞(201B7株、京都大学iPS 細胞研究所(iPSアカデミアジャパン株式会社))をbFGF添加又は無添加の培地(StemSure hPSC Medium、和光純薬工業(株)製)で培養し、培養3日目、5日目、7日目に、細胞を回収した。
実施例1(2)と同様の方法で、上記(1)で回収した培養3日目、5日目、7日目の細胞から、それぞれTotal RNAを抽出した。
実施例1(3)と同様の方法で上記(2)で抽出したTotal RNA、及びHMSC-bm細胞のTOTAL RNAの1μgを、それぞれDNAase処理した。
上記(3)でDNase処理したTotal RNA 9.5μLに、下記のプライマーを含む混合Primer(各5μM)1μLを加えた。下記プライマーは、すべてシグマアルドリッチ社製である。
・OCT3/4 mRNAの増幅プライマー、GTTCTTGAAGCTAAGCTGCAG (配列番号5、GenBank Accession No. NM_002701 : 641-661)、
・NANOG mRNAの増幅プライマー、GTTCTGGAACCAGGTCTTCAC (配列番号6、GenBank Accession No. NM_024865 : 631-651)、
・SOX2 mRNAの増幅プライマー、GACCACACCATGAAGGCATTC (配列番号7、GenBank Accession No. NM_003106 : 572-592)、
・GAPDH mRNAの増幅プライマー、GTCTACATGGCAACTGTGAGG (配列番号8、GenBank Accession No. NM_002046 : 1303-1323)
上記(4)で得られたcDNA 1μL、蒸留水5μL、2×PCR Buffer for KOD FX Neo(東洋紡(株)製)12.5μL、2 mM dNTPs(東洋紡(株)製)4μL、KOD FX Neo(東洋紡(株)製)0.5μL(0.5U)、各Forward primer(10μM)1μL、各Reverse primer(10μM)1μLを混合した。
フォワードプライマー: CTACTCTTACATCTCGCTGACCG(配列番号9)
リバースプライマー: GAATCTTGATGAAGCAGTCGTTG(配列番号10)
増幅鎖長 : 179bp
フォワードプライマー: CTTGGAGACCTCTCAGCCTGAG(配列番号11)
リバースプライマー: CTTCAGGAGCTTGGCAAATTG(配列番号12)
増幅鎖長 : 196bp
フォワードプライマー: CACCTATGCCTGTGATTTGTGG(配列番号13)
リバースプライマー: CATTGAGTACACACAGCTGGGTG(配列番号14)
増幅鎖長 : 267bp
フォワードプライマー: GTATCAGGAGTTGTCAAGGCAGAG(配列番号15)
リバースプライマー: CAGCTCCGTCTCCATCATGTTG(配列番号16)
増幅鎖長 : 434bp
フォワードプライマー: GTCACCAGGGCTGCTTTTAAC(配列番号17)
リバースプライマー: GGCATTGCTGATGATCTTGAG(配列番号18)
増幅鎖長 : 399bp
PCR増幅産物5μLと、6×Loading Buffer Double Dye(ニッポンジーン(株)製)1μLとを混合し、これを1.5%アガロースゲルにて電気泳動した。染色はGelRed核酸ゲル染色液(和光純薬工業(株)製)にて行った。
結果を図2に併せて示す。
(1)幹細胞の培養と分化誘導処理
hiPS細胞(201B7株、京都大学iPS 細胞研究所(iPSアカデミアジャパン株式会社))、及び比較として、分化した細胞であるHDF細胞(ヒト正常細胞由来繊維芽細胞、ロンザジャパン(株)製)を、bFGF添加(100ng/mL)又は無添加の培地(StemSure hPSC Medium、和光純薬工業(株)製)で3回継代培養し、培養6日目に細胞を回収した。
市販の核酸抽出試薬であるキットISOGEN((株)ニッポンジーン製)を用い、現品説明書に従って、上記(1)で回収した細胞から、Total RNAを抽出した。
実施例1(3)と同様の方法で、上記(2)で抽出したTotal RNAの1μgを、それぞれDNase処理した。
上記(3)でDNase処理したTotal RNA 9.5μLに、下記の各mRNAを標的とする増幅プライマーを含む混合Primer(各5μM)1μLを加えた。下記プライマーは、すべてシグマアルドリッチ社製である。
・FOXB2 mRNAの増幅プライマー、CAGAAGCTACCCTTGCCAG(配列番号4、GenBank Accession No. NM_001013735 : 242-260)
・OCT3/4 mRNAの増幅プライマー、GTTCTTGAAGCTAAGCTGCAG(配列番号5、GenBank Accession No. NM_002701 : 641-661)
・NANOG mRNAの増幅プライマー、GTTCTGGAACCAGGTCTTCAC(配列番号6、GenBank Accession No. NM_024865 : 631-651)
・SOX2 mRNAの増幅プライマー、GACCACACCATGAAGGCATTC(配列番号7、GenBank Accession No. NM_003106 : 572-592)
・FGF5 mRNAの増幅プライマー、 CTCCCTGAACTTGCAGTCATC(配列番号19、GenBank Accession No. NM_004464 : 709-729)
・CDX2 mRNAの増幅プライマー、CCTGAGGAGTCTAGCAGAGTC(配列番号20、GenBank Accession No. NM_001265 : 1359-1379)
・GATA4 mRNAの増幅プライマー、GATTACGCAGTGATTATGTCCC(配列番号21、GenBank Accession No. NM_001308094 : 1110-1131)
・GATA6 mRNAの増幅プライマー、CATCTTGACCCGAATACTTGAG(配列番号22、GenBank Accession No. NM_005257 : 1961-1982)
・SOX17 mRNAの増幅プライマー、CCCAGGAGTCTGAGGATTTCC(配列番号23、GenBank Accession No. NM_022454 : 1515-1535)
・GAPDH mRNAの増幅プライマー、GTCTACATGGCAACTGTGAGG(配列番号8、GenBank Accession No. NM_002046 : 1303-1323)
上記(4)で得られたcDNA 1μL、蒸留水5μL、2× PCR Buffer for KOD FX Neo(東洋紡(株)製)12.5μL、2 mM dNTPs(東洋紡(株)製)4μL、KOD FX Neo(東洋紡(株)製)0.5μL(0.5U)、各Forward primer(10μM)1μL、各Reverse primer(10μM)1μLを混合した。
Forward primer : CTACTCTTACATCTCGCTGACCG(配列番号9)
Reverse primer : GAATCTTGATGAAGCAGTCGTTG(配列番号10)
増幅鎖長 : 179bp
Forward primer : CTTGGAGACCTCTCAGCCTGAG(配列番号11)
Reverse primer : CTTCAGGAGCTTGGCAAATTG(配列番号12)
増幅鎖長 : 196bp
Forward primer : CACCTATGCCTGTGATTTGTGG(配列番号13)
Reverse primer : CATTGAGTACACACAGCTGGGTG(配列番号14)
増幅鎖長 : 267bp
Forward primer : GTATCAGGAGTTGTCAAGGCAGAG(配列番号15)
Reverse primer : CAGCTCCGTCTCCATCATGTTG(配列番号16)
増幅鎖長 : 434bp
Forward primer : GCAGAGCAGTTTCCAGTGGAG(配列番号24)
Reverse primer : GTATTCCTACAATCCCCTGAGAC(配列番号25)
増幅鎖長 :176bp
Forward primer : CAAATATCGAGTGGTGTACACG(配列番号26)
Reverse primer : GACACTTCTCAGAGGACCTGG(配列番号27)
増幅鎖長 :274bp
Forward primer : CAGCTCCTTCAGGCAGTGAGAG(配列番号28)
Reverse primer : CGGGAGACGCATAGCCTTGTG(配列番号29)
増幅鎖長 :246bp
Forward primer : GCTTGTGGACTCTACATGAAAC(配列番号30)
Reverse primer : GCTGCAATCATCTGAGTTAGAAG(配列番号31)
増幅鎖長 :183bp
Forward primer : CGGAATTTGAACAGTATCTGC(配列番号32)
Reverse primer : GCTCCTCCAGGAAGTGTGTAAC(配列番号33)
増幅鎖長 :226bp
Forward primer : GTCACCAGGGCTGCTTTTAAC(配列番号17)
Reverse primer : GGCATTGCTGATGATCTTGAG(配列番号18)
増幅鎖長 : 399bp
上記(5)で得られたPCR増幅産物5μLと、6×Loading Buffer Double Dye((株)ニッポンジーン製)1μLとを混合し、これを1.5%アガロースゲルにて電気泳動した。染色はGelRed核酸ゲル染色液(和光純薬工業(株)製)にて行った。
結果を図3に併せて示す。
マウスES細胞をLIF無添加培地で培養して分化誘導処理し、FOXB2 mRNA及び公知の未分化マーカーの発現を、RT-PCR法により検出した。
mES細胞(D3株、ATCC、b723512)を、LIF添加(1000Unit)又は無添加の培地(StemSure DMEM、StemSure Serum replacement、MEM非必須アミノ酸溶液、L-グルタミン溶液、StemSure 2-メルカプトエタノール溶液、和光純薬工業(株)製)で3回継代培養し、培養3日目、5日目、7日目、に細胞を回収した。
市販の核酸抽出試薬であるキットISOGEN((株)ニッポンジーン製)を用い、現品説明書に従って、上記(1)で回収した細胞から、Total RNAを抽出した。
上記(2)で抽出したTotal RNAの1μgに、全量17μLになるように蒸留水を加え、10X Reaction Buffer(プロメガ(株)製)を2μL、RQ1 RNase-Free DNase(プロメガ(株)製)を1μL(1U)を加え混合し、37℃、20分間インキュベートした。その後、Stop Buffer(20mM EGTA)(プロメガ(株)製)を1μL加え混合し、65℃、10分間インキュベートした。その後、反応物に結合Buffer(5.5Mグアニジン塩酸塩(和光純薬工業(株)製)、20mM Tris-HCl pH6.6)を100μL加え混合した後、エコノスピン(核酸精製用シリカメンブレンスピンカラム、(株)ジーンデザイン製)に移し、12000×g、室温、1分間遠心分離し、チューブの溶液を除去した。次いで、チューブに洗浄Buffer(2mM Tris-HCl pH7.5((株)ニッポンジーン製)、80% エタノール(和光純薬工業(株)製)を500μL添加し、12000×g、室温、1分間遠心分離し、チューブの溶液を除去した。更に12000×g、室温、1分間遠心分離した後、エコノスピン(mRNAが結合している)を新しいチューブに交換し、溶出Buffer(10mMTris-HCl pH8.0)((株)ニッポンジーン製)を50μL添加し、12000×g、室温、1分間遠心分離してTotal RNAを回収した。その後、エタノール沈殿を行い、得られた沈殿物を蒸留水9.5μLに溶解した。
上記(3)でDNase処理したTotal RNA 9.5μLに、下記の各mRNAを標的とする増幅プライマーを含む混合Primer(各5μM)1μLを加えた。下記プライマーは、すべてシグマアルドリッチ社製である。
・Foxb2 mRNAの増幅プライマー、CATGATGAACTTGTAGATGTC(配列番号37、GenBank Accession No. NM_008023 : 302-322)
・Oct3/4 mRNAの増幅プライマー、CATGTTCTTAAGGCTGAGCTGC(配列番号38、GenBank Accession No. NM_013633 : 617-638)
・Nanog mRNAの増幅プライマー、CTGAATCAGACCATTGCTAGTC(配列番号39、GenBank Accession No. NM_028016 : 388-408)
・Sox2 mRNAの増幅プライマー、CAACGATATCAACCTGCATGG(配列番号40、GenBank Accession No. NM_011443 : 2120-2140)
・Klf2 mRNAの増幅プライマー、GAACTGGTGGCAGAGTCATTTTC(配列番号41、GenBank Accession No. NM_008452 : 1205-1227)
・Esrrb mRNAの増幅プライマー、GATTCGAGACGATCTTAGTCAATG(配列番号42、GenBank Accession No. NM_011934 : 957-980)
・Fgf5 mRNAの増幅プライマー、GACGCATAGGTATTATAGCTG(配列番号43、GenBank Accession No. NM_010203 : 729-749)
・Gapdh mRNAの増幅プライマー、CTTGATGTCATCATACTTGGC(配列番号44、GenBank Accession No. NM_001289726 :843-863)
上記(4)で得られたcDNA 1μL、蒸留水5μL、2× PCR Buffer for KOD FX Neo(東洋紡(株)製)12.5μL、2 mM dNTPs(東洋紡(株)製)4μL、KOD FX Neo(東洋紡(株)製)0.5μL(0.5U)、各Forward primer(10μM)1μL、各Reverse primer(10μM)1μLを混合した。
使用した各Primerの塩基配列は、以下の通りである。下記プライマーは、すべてシグマアルドリッチ社製である。
Forward primer : CTTTCCAAGAGGCGTTAAGGC(配列番号45)
Reverse primer : CTCAGAGGCAGCATCTTCTCAG(配列番号46)
増幅鎖長 : 169bp
Forward primer : GAACCTGGCTAAGCTTCCAAG(配列番号47)
Reverse primer : GCTTGGCAAACTGTTCTAGCTC(配列番号48)
増幅鎖長 : 339bp
Forward primer : GCATTAGACATTTAACTCTTCTTTC(配列番号49)
Reverse primer : CTTGAAGAGGCAGGTCTTCAG(配列番号50)
増幅鎖長 : 299bp
Forward primer : GAATCGGACCATGTATAGATCTG(配列番号51)
Reverse primer : CATTTGATTGCCATGTTTATCTCG(配列番号52)
増幅鎖長 : 208bp
Forward primer : GAAGCCTTATCATTGCAACTGG(配列番号53)
Reverse primer : CTGTCCTAAGGTCCAATAAATAGC(配列番号54)
増幅鎖長 : 273bp
Forward primer : GCAAGAGCTACGAGGACTGTAC(配列番号55)
Reverse primer : GTTTGGTGATCTCACATTCATTG(配列番号56)
増幅鎖長 : 231bp
Forward primer : GAACATAGCAGTTTCCAGTGG(配列番号57)
Reverse primer : GTTGCTGAAAACTCCTCGTATTC(配列番号58)
増幅鎖長 : 195bp
Forward primer : GTTCCAGTATGACTCCACTCACG(配列番号59)
Reverse primer : CATTGCTGACAATCTTGAGTGAG(配列番号60)
増幅鎖長 : 311bp
上記(5)で得られたPCR増幅産物5μLと、6×Loading Buffer Double Dye((株)ニッポンジーン製)1μLとを混合し、これを1.5%アガロースゲルにて電気泳動した。染色はGelRed核酸ゲル染色液(和光純薬工業(株)製)にて行った。
結果を図4に併せて示す。
(1)幹細胞の培養と分化誘導処理
hiPS細胞(201B7株、京都大学iPS 細胞研究所(iPSアカデミアジャパン株式会社))を以下の培地で培養した。
結果を図5に示す。
1)抗ヒトFOXB2蛋白質抗体固定化ELISA用マイクロプレートの調製
抗ヒトFOXB2蛋白質抗体の溶液(50mM MOPS緩衝液(pH7.0))をELISA用マイクロプレート(Nunk社製)の各ウェルに分注後24時間静置して、抗ヒトFOXB2蛋白質抗体を固定化したマクロプロレートを得る。
2)ペルオキシダーゼ標識抗FOXB2蛋白質抗体の調製
抗ヒトFOXB2蛋白質抗体を常法によりペルオキシダーゼ標識する。
3)試料の調製
分化誘導後3日目のhiPS細胞を回収し、ソニケーションによりhiPS細胞を破壊して、細胞のライセートを得る。得られたライセートを緩衝液に溶解させて試料とする。
4)測定
上記3)で調製した試料を、上記1)で調製した抗FOXB2蛋白質抗体固定化ELISA用マイクロプレートの各ウェルに添加し、37℃で1時間程度反応させる。次いで各ウェルを緩衝液で回洗浄する。
上記2)で調製したペルオキシダーゼ標識抗FOXB2蛋白質抗体をそれぞれ各ウェルに分注し、37℃で1時間程度反応させる。各ウェルを緩衝液で、次いで蒸留水で洗浄し、TMB(3,3',5,5'-テトラメチルベンジジン)溶液(和光純薬工業(株)製)を各ウェルに50μLずつ添加し、25℃、30分間反応させる。その後、反応停止液(1Mりん酸溶液)を各ウェルに50μL ずつ添加して反応を停止させる。450nmにおける吸光度を、Vmax (モレキュラーデバイス社製) を用いて測定する。
その結果、FOXB2蛋白質が検出された場合には、試料として用いたhiPS細胞は分化した状態であると判定される。又は、試料として用いたhiPS細胞の細胞群には、分化した状態の細胞が含まれると判定される。
1)試料の調製
分化誘導後3日目のhiPS細胞を回収し、ソニケーションによりhiPS細胞を破壊して、細胞のライセートを得る。得られたライセートを緩衝液に溶解させて試料とする。
2)ペルオキシダーゼ標識抗FOXB2蛋白質抗体の調製
抗ヒトFOXB2蛋白質抗体を常法によりペルオキシダーゼ標識する。
3)ウエスタンブロッティング
上記1)で得られた試料をSuperSepTM(電気泳動用ゲル、和光純薬工業(株),5-20%のグラジェントゲル)にアプライして、SDS-PAGE電気泳動(定電流25mA)を行う。次いで、泳動後の画分を、セミドライブロッティング法にてPVDFメンブレンに転写する。
PBS-T(Phosphate Buffered Saline with TweenTM 20、pH 7.4)にブロックエース(DSファーマバイオメディカル(株)製)を溶解させてブロッキング液とする。このブロッキング液に上記転写後のPVDFメンブレンを浸漬させ、1時間室温にてブロッキング処理した後、PVDFメンブレンを洗浄し、ブロッキング液に浸漬させる。
次いで、上記2)で得られたペルオキシダーゼ標識抗ヒトFOXB2蛋白質抗体をブロッキング液に加えて室温で1時間程度浸漬させる。PVDFメンブレンを洗浄し、ECLTM Prime Western Blotting Detection Reagent(ペルオキシダーゼの化学発光基質、GE Healthcare製)で発光させ、LAS4000(富士フイルム(株)製)を用い、露光時間10秒で検出する。
その結果、FOXB2蛋白質が検出された場合には、試料として用いたhiPS細胞は分化した状態であると判定される。又は、試料として用いたhiPS細胞の細胞群には、分化した状態の細胞を含むと判定される。
した状態の細胞が含まれる判定される。
Claims (15)
- 幹細胞のFOXB2遺伝子の発現を検出し、その結果に基づいて判定を行う、細胞の分化状態の判定方法。
- FOXB2遺伝子の発現の検出を、FOXB2 mRNA又はFOXB2蛋白質を検出することにより行う、請求項1に記載の方法。
- FOXB2 mRNAが検出された場合に、その細胞が分化した状態であると判定する、請求項2に記載の方法。
- FOXB2蛋白質が検出された場合に、その細胞が分化した状態であると判定する、請求項2に記載の方法。
- FOXB2 mRNAが、配列番号1又は配列番号34で表される塩基配列を有する、又は配列番号1又は配列番号34で表される塩基配列と70%以上の相同性を有する、請求項2に記載の方法。
- FOXB2 mRNAが、配列番号2若しくは配列番号35で表されるアミノ酸配列又はその1個若しくは数個のアミノ酸が欠失、置換、若しくは付加されたアミノ酸配列をコードする、請求項2に記載の方法。
- FOXB2蛋白質が配列番号2若しくは配列番号35で表されるアミノ酸配列又はその1個若しくは数個のアミノ酸が欠失、挿入、置換、若しくは付加されたアミノ酸配列を有する、請求項2に記載の方法。
- FOXB2 mRNAの検出をRT-PCT法により行う、請求項2に記載の方法
- 幹細胞がiPS細胞又はES細胞である、請求項1に記載の方法。
- FOXB2遺伝子由来のmRNA又は蛋白質から選択される、分化マーカー。
- FOXB2遺伝子由来のmRNAが、配列番号1又は配列番号34で表される塩基配列を有する、又は配列番号1又は配列番号34で表される塩基配列と70%以上の相同性を有する、請求項10に記載の分化マーカー。
- FOXB2遺伝子由来のmRNAが、配列番号2若しくは配列番号35で表されるアミノ酸配列、又はその1個若しくは数個のアミノ酸が欠失、置換、若しくは付加されたアミノ酸配列をコードするものである、請求項10に記載の分化マーカー。
- FOXB2遺伝子由来の蛋白質が、配列番号2若しくは配列番号35で表されるアミノ酸配列、又はその1個若しくは数個のアミノ酸が欠失、置換、若しくは付加されたアミノ酸配列を有する、請求項10に記載の分化マーカー。
- 幹細胞の分化マーカーである、請求項10に記載の分化マーカー。
- 幹細胞がiPS細胞又はES細胞である、請求項14に記載の分化マーカー。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020167035101A KR20170044061A (ko) | 2014-08-20 | 2015-08-19 | 간세포의 분화 상태의 판정 방법 및 이것에 사용되는 신규한 분화 마커 |
CN201580031805.5A CN106661604A (zh) | 2014-08-20 | 2015-08-19 | 干细胞的分化状态的判定方法以及该判定方法中使用的新的分化标记 |
EP15833859.0A EP3184643B1 (en) | 2014-08-20 | 2015-08-19 | Method for determining state of differentiation of stem cells, and novel differentiation marker used therefor |
US15/501,761 US10711307B2 (en) | 2014-08-20 | 2015-08-19 | Method for determining state of differentiation of stem cells, and novel differentiation marker used therefor |
JP2016544240A JP6593335B2 (ja) | 2014-08-20 | 2015-08-19 | 幹細胞の分化状態の判定方法及びこれに用いられる新規な分化マーカー |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-167800 | 2014-08-20 | ||
JP2014167800 | 2014-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016027842A1 true WO2016027842A1 (ja) | 2016-02-25 |
Family
ID=55350784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/073281 WO2016027842A1 (ja) | 2014-08-20 | 2015-08-19 | 幹細胞の分化状態の判定方法及びこれに用いられる新規な分化マーカー |
Country Status (6)
Country | Link |
---|---|
US (1) | US10711307B2 (ja) |
EP (1) | EP3184643B1 (ja) |
JP (1) | JP6593335B2 (ja) |
KR (1) | KR20170044061A (ja) |
CN (1) | CN106661604A (ja) |
WO (1) | WO2016027842A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018121659A (ja) * | 2014-05-01 | 2018-08-09 | 株式会社島津製作所 | 細胞の分化状態の評価方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011091270A2 (en) * | 2010-01-21 | 2011-07-28 | The Regents Of The University Of Michigan | Biomarkers for lung disease monitoring |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
FI20105166A0 (fi) * | 2010-02-19 | 2010-02-19 | Suomen Punainen Risti Veripalv | Menetelmä kantasolupopulaation erilaistumistilan osoittamiseksi |
CN102822333A (zh) * | 2010-03-23 | 2012-12-12 | 奥林巴斯株式会社 | 监控干细胞的分化状态的方法 |
CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
-
2015
- 2015-08-19 JP JP2016544240A patent/JP6593335B2/ja not_active Expired - Fee Related
- 2015-08-19 US US15/501,761 patent/US10711307B2/en active Active
- 2015-08-19 WO PCT/JP2015/073281 patent/WO2016027842A1/ja active Application Filing
- 2015-08-19 EP EP15833859.0A patent/EP3184643B1/en active Active
- 2015-08-19 CN CN201580031805.5A patent/CN106661604A/zh active Pending
- 2015-08-19 KR KR1020167035101A patent/KR20170044061A/ko not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011091270A2 (en) * | 2010-01-21 | 2011-07-28 | The Regents Of The University Of Michigan | Biomarkers for lung disease monitoring |
Non-Patent Citations (1)
Title |
---|
VAN ROON EDDY H ET AL.: "BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer", CLINICAL EPIGENETICS, vol. 5, 16 January 2013 (2013-01-16), pages 2, XP021143224, DOI: doi:10.1186/1868-7083-5-2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018121659A (ja) * | 2014-05-01 | 2018-08-09 | 株式会社島津製作所 | 細胞の分化状態の評価方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20170044061A (ko) | 2017-04-24 |
JPWO2016027842A1 (ja) | 2017-06-01 |
EP3184643B1 (en) | 2020-02-19 |
CN106661604A (zh) | 2017-05-10 |
US20170342490A1 (en) | 2017-11-30 |
JP6593335B2 (ja) | 2019-10-23 |
EP3184643A4 (en) | 2018-01-17 |
EP3184643A1 (en) | 2017-06-28 |
US10711307B2 (en) | 2020-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111656179B (zh) | 用于使用表位电泳进行样品分析的装置 | |
EP3277834B1 (en) | Methods of capturing sperm nucleic acids | |
Steilmann et al. | The interaction of modified histones with the bromodomain testis-specific (BRDT) gene and its mRNA level in sperm of fertile donors and subfertile men | |
WO2018045141A1 (en) | Analysis of chromatin using a nicking enzyme | |
CN108220428B (zh) | 用于检测胃癌的组合物及其试剂盒和用途 | |
EP1977013A2 (en) | Epigenetic analyses | |
Nilsson et al. | High salt buffer improves integrity of RNA after fluorescence-activated cell sorting of intracellular labeled cells | |
Graham et al. | Ensemble and Single-Molecule analysis of Non-Homologous end joining in frog egg extracts | |
JP6593335B2 (ja) | 幹細胞の分化状態の判定方法及びこれに用いられる新規な分化マーカー | |
KR101828812B1 (ko) | 줄기세포의 세포노화 검출용 키트 | |
US11155852B2 (en) | RT-qPCR analysis of micro-dissected material from stained FFPET section | |
WO2012115493A9 (ko) | 암에 대한 바이오마커 및 이를 이용한 암 진단 | |
WO2017141672A1 (ja) | 細胞の分化状態の判定方法、及びこれに用いられる新規な分化マーカー | |
Williams et al. | The development of a method of suspension RNA-FISH for forensically relevant epithelial cells using LNA probes | |
Fenstermaker et al. | A proximity ligation-based method to detect RNA-DNA association | |
Ma et al. | Blood-derived integration-free induced pluripotent stem cells (iPSCs) from one 53-years-old male donor with APOE-ε4/ε4 genotype | |
Dunbar | Nucleic acid sample preparation techniques for bead-based suspension arrays | |
Rosàs-Canyelles et al. | Multimodal detection of protein isoforms and nucleic acids from low starting cell numbers | |
Yasui et al. | Highly sensitive detection of human pluripotent stem cells by loop-mediated isothermal amplification | |
Duckworth et al. | Highly Multiplexed and Simultaneous Characterization of Protein and RNA in Single Cells by Flow or Mass Cytometry Platforms Using Proximity Ligation Assay for RNA | |
Uhlmann et al. | Application of In Situ-PCR for the Detection of Intracellular mRNAs | |
Salazar et al. | An elution independent collection device (EICD) for rapid collection of Anaplasma marginale DNA from blood samples | |
Policicchio | Examining epigenetic variation in the brain in mental illness | |
JP2019180308A (ja) | ニッキングエンザイムを利用した測定方法 | |
KR20140094905A (ko) | 트리톤 X-100 첨가에 의한 세포 내 miRNA의 추출 효율의 증가 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15833859 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016544240 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167035101 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015833859 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015833859 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15501761 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |